[{"text": "Adma Biologics (ADMA) Rises Higher Than Market: Key Facts Zacks Equity Research Thu, Jan 23, 2025, 1:50 AM 2 min read In This Article: ADMA +1.98% The latest trading session saw Adma Biologics (ADMA) ending at $16.47, denoting a +1.92% adjustment from its last day's close. This move outpaced the S&P 500's daily gain of 0.61%. Elsewhere, the Dow saw an upswing of 0.3%, while the tech-heavy Nasdaq appreciated by 1.28%. Shares of the infectious disease drug developer have depreciated by 7.18% over the course of the past month, underperforming the Medical sector's gain of 1.64% and the S&P 500's gain of 2.08%. Market participants will be closely following the financial results of Adma Biologics in its upcoming release. In that report, analysts expect Adma Biologics to post earnings of $0.15 per share. This would mark year-over-year growth of 275%. In the meantime, our current consensus estimate forecasts the revenue to be $112.2 million, indicating a 51.83% growth compared to the corresponding quarter of the prior year. Furthermore, it would be beneficial for investors to monitor any recent shifts in analyst projections for Adma Biologics. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability. Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system. The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Within the past 30 days, our consensus EPS projection has moved 11.61% lower. Right now, Adma Biologics possesses a Zacks Rank of #3 (Hold). Digging into valuation, Adma Biologics currently has a Forward P/E ratio of 23.59. For comparison, its industry has an average Forward P/E of 21.95, which means Adma Biologics is trading at a premium to the group. The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 72, positioning it in the top 29% of all 250+ industries. The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Story Continues Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report ADMA Biologics Inc (ADMA) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ADMA", "date": "2025-01-23T01:50:20", "sentiment": {"score": 0.8127849511802197, "confidence": 0.8646665215492249, "probabilities": {"positive": 0.8646665215492249, "negative": 0.0518815703690052, "neutral": 0.08345188200473785}}, "embedding": [-0.09808649122714996, -0.04211238771677017, -0.044183410704135895, 0.020503370091319084, -0.03639066964387894, -0.08429260551929474, -0.0011834376491606236, 0.17489616572856903, 0.1344057321548462, 0.14529135823249817, -0.13856323063373566, 0.1182418167591095, -0.020214851945638657, 0.021635329350829124, -0.09170842915773392, 0.015645883977413177, -0.012862373143434525, -0.03325898200273514, -0.09113895148038864, 0.09562382102012634, -0.009610772132873535, 0.03453528881072998, 0.060040026903152466, -0.014981262385845184, 0.06209341064095497, -0.01957591436803341, -0.032716650515794754, 0.05478796735405922, -0.20058993995189667, -0.07644987106323242, -0.07233873009681702, 0.0981721431016922, 0.14763379096984863, -0.0896686464548111, -0.04970911890268326, -0.07384104281663895, -0.08145339787006378, 0.06268966197967529, 0.11368526518344879, 0.07648985087871552, -0.0046201441437006, 0.0331311970949173, -0.13326972723007202, -0.02117721177637577, -0.07610677182674408, -0.1779397428035736, -0.006770384963601828, 0.04699884355068207, 0.04971865564584732, 0.08294486254453659, -0.24068576097488403, -0.0428926944732666, -0.03196850046515465, 0.012288184836506844, -0.055709630250930786, 0.03079574555158615, -0.1013510674238205, -0.15891030430793762, -0.014956715516746044, 0.0026415311731398106, 0.02268599346280098, 0.09317559003829956, 0.018476981669664383, 0.0031195953488349915, 0.23369629681110382, -0.03308520466089249, 0.019726915284991264, 0.05662183463573456, -0.09806739538908005, 0.06998758018016815, 0.031490258872509, -0.0007240157574415207, -0.07377669215202332, 0.002565720584243536, -0.11531095206737518, 0.11515337228775024, 0.08674268424510956, 0.08701492846012115, 0.14296120405197144, -0.13692787289619446, 0.11038447916507721, -0.04971197992563248, -0.1058829128742218, -0.05282074958086014, -0.023334460332989693, -0.007504729554057121, 0.12564294040203094, 0.08526409417390823, 0.11733376979827881, 0.02260018140077591, 0.09164699912071228, -0.1049451231956482, -0.03224046528339386, 0.023699583485722542, 0.0504256971180439, 0.01679726131260395, -0.07624629139900208, -0.08933654427528381, 0.07056458294391632, 0.07142563164234161, 0.01309246476739645, 0.09567735344171524, -0.016067123040556908, -0.1284973919391632, 0.02795628271996975, -0.11736328154802322, 0.020331833511590958, -0.002476012334227562, 0.0619167685508728, 0.07925219088792801, -0.035934001207351685, 0.09862175583839417, -0.1013997420668602, -0.021265259012579918, -0.07959224283695221, 0.12347812950611115, -0.026116346940398216, 0.004358368460088968, 0.11352088302373886, 0.05175187438726425, 0.13010108470916748, 0.07070580869913101, 0.04978860914707184, -0.009597266092896461, 0.076331727206707, 0.05230443552136421, -0.16284453868865967, 7.491017013503528e-33, 0.044278334826231, 0.07167044281959534, 0.05632702261209488, -0.011464769020676613, -0.061241552233695984, -0.0023703640326857567, 0.010009139776229858, -0.09911441057920456, -0.03162432461977005, -0.0484117828309536, -0.21247225999832153, 0.16524358093738556, -0.06129909306764603, 0.07728230953216553, -0.008551542647182941, -0.019892441108822823, -0.0090639628469944, 0.04593241959810257, -0.03674399107694626, -0.0273769311606884, -0.024802669882774353, 0.005832829978317022, -0.12569965422153473, 0.01784452050924301, 0.022594889625906944, 0.03447096049785614, -0.11753395944833755, 0.05059868097305298, -0.09413547813892365, 0.05529747158288956, -0.012671909295022488, 0.0305943563580513, -0.012017079629004002, -0.15527085959911346, -0.007381209637969732, -0.06418662518262863, -0.029497548937797546, 0.0004082638770341873, 0.14727261662483215, 0.02026990056037903, -0.08422389626502991, 0.012300537899136543, -0.11492306739091873, -0.1012701466679573, 0.003873621579259634, 0.033152006566524506, -0.1291218101978302, 0.029389407485723495, -0.05904507637023926, -0.028651831671595573, -0.04431453347206116, -0.01206896360963583, 0.06843869388103485, -0.08306954801082611, -0.15004399418830872, -0.032237306237220764, -0.02732248604297638, -0.17342671751976013, 0.009493823163211346, 0.12806712090969086, 0.0068216510117053986, 0.163656547665596, 0.046301957219839096, -0.00722297839820385, -0.27404287457466125, 0.13525782525539398, 0.03524887189269066, 0.029713068157434464, -0.062286630272865295, 0.19010120630264282, 0.007296578027307987, 0.018256347626447678, 0.11428822576999664, -0.09501941502094269, 0.05894419178366661, -0.014514997601509094, 0.011460445821285248, 0.0005252053961157799, -0.02567165344953537, 0.10041758418083191, -0.04122273623943329, -0.05895224213600159, -0.05055656656622887, 0.03420661762356758, 0.053372640162706375, -0.014544946141541004, 0.00805631559342146, 0.03864346444606781, -0.017497655004262924, -0.015699759125709534, 0.03478147089481354, 0.02609235793352127, -0.14393746852874756, 0.15201020240783691, 0.015896160155534744, -1.0271590125656108e-32, -0.15837644040584564, 0.0480908527970314, 0.010582797229290009, 0.010595440864562988, -0.08987288177013397, 0.01084056869149208, 0.06219800189137459, 0.14524716138839722, -0.019350748509168625, -0.05342535674571991, -0.032221898436546326, 0.0736788883805275, -0.12091987580060959, 0.04144194349646568, 0.002757761627435684, -0.011972717940807343, -0.01137688010931015, -0.09050028026103973, -0.0001247059553861618, 0.04610603675246239, 0.010392962023615837, 0.24787533283233643, -0.1123540997505188, 0.17070576548576355, 0.06033492088317871, 0.04248979687690735, -0.0035454544704407454, 0.14424732327461243, -0.011398430913686752, -0.14734159409999847, -0.0181538388133049, -0.02447441592812538, -0.10806602984666824, 0.04465431347489357, -0.02578134462237358, 0.008782871067523956, 0.06108235567808151, -0.21935397386550903, 0.0012177936732769012, -0.008478614501655102, 0.11443367600440979, 0.0017258170992136002, 0.0008873911574482918, -0.004323458299040794, 0.16063548624515533, 0.020910652354359627, 0.1327444165945053, -0.011265664361417294, 0.1889238953590393, 0.05605065077543259, 0.057425644248723984, 0.03178171440958977, 0.0010228175669908524, 0.10444768518209457, -0.12772327661514282, -0.001099950633943081, -0.11128021031618118, -0.024755025282502174, -0.0759749487042427, 0.03796829283237457, 0.03343011066317558, 0.09780709445476532, -0.009191285818815231, 0.013864714652299881, -0.08684992790222168, 0.0034242337569594383, 0.12881024181842804, -0.06880635768175125, 0.022763729095458984, -0.09118972718715668, 0.014495604671537876, -0.041088659316301346, 0.05121913552284241, -0.08836642652750015, -0.00790602806955576, 0.16322307288646698, -0.09691734611988068, -0.09195791184902191, -0.06467556953430176, 0.0005924180150032043, 0.003697892650961876, 0.05570167303085327, 0.06023549288511276, -0.009033257141709328, -0.10376764833927155, 0.08516846597194672, 0.04226217418909073, -0.005696143954992294, -0.12974813580513, -0.012518629431724548, -0.09063679724931717, -0.15255574882030487, -0.1485152244567871, -0.02239128202199936, -0.00889817625284195, -1.0046755960502196e-07, 0.11624174565076828, 0.015320525504648685, 0.08254273980855942, -0.05616416782140732, 0.12142238020896912, -0.017909301444888115, 0.02167389914393425, 0.05656571686267853, 0.15043559670448303, 0.14610597491264343, 0.08668814599514008, 0.0837707370519638, -0.25319674611091614, 0.083771713078022, -0.11122958362102509, 0.04780988767743111, -0.1285499632358551, 0.023021679371595383, -0.06277509778738022, -0.17867127060890198, -0.016798734664916992, 0.11790818721055984, 0.09211455285549164, -0.06766083091497421, 0.07127228379249573, -0.0781218558549881, -0.040642332285642624, -0.03332289308309555, -0.030007895082235336, -0.005063645541667938, 0.06655876338481903, -0.024017591029405594, -0.009015949442982674, 0.1172022670507431, -0.03957275301218033, -0.1255517303943634, 0.09733013808727264, -0.024252459406852722, 0.05568686127662659, 0.10959650576114655, 0.011408496648073196, -0.07125887274742126, -0.034839753061532974, -0.010462149977684021, -0.03236575052142143, -0.07046624273061752, -0.10694731771945953, 0.019581086933612823, 0.08719086647033691, -0.23896640539169312, 0.09711681306362152, -0.028599755838513374, -0.03770838677883148, -0.04894512891769409, -0.022755105048418045, 0.041067324578762054, -0.14354175329208374, -0.013389633037149906, -0.17621438205242157, -0.027665700763463974, 0.1397777646780014, -0.2155238837003708, -0.03637377917766571, 0.10996949672698975], "changes": {"1wk": -0.5464490366730929}}, {"text": "BioTek reMEDys Names Neal Fitzpatrick Chief Strategy Officer Business Wire Thu, Jan 23, 2025, 8:03 PM 2 min read NEW CASTLE, Del., January 23, 2025 --( BUSINESS WIRE )-- BioTek reMEDys , a multi-site national integrated infusion therapy provider focused on providing support to people with rare diseases, has named Neal C. Fitzpatrick as its Chief Strategy Officer. Fitzpatrick recently served as Chief Commercial Officer at a biotech company, charged with leading the organization through a period of high growth. Before this, he served as Vice-President of Sales at ADMA Biologics, where he repositioned an essential product from hospital settings to alternative care sites, such as office-based physicians, during the COVID-19 pandemic. He built a high-performing sales team with solid experience, strong relationships, and high moral character, focusing on patient-centric outcomes and fostering a culture of open communication. Fitzpatrick also previously served in leadership positions at Kedrion Biopharma and United Therapeutics. \"We are excited to add Neal to our leadership team in such a pivotal role,\" said BioTek reMEDys\u2019 CEO and founder Chaitanya Gadde. \"Neal has built a well-earned reputation for his ability to drive stakeholder satisfaction while helping health organizations realize their full potential and impact. With his decades of success in the biotechnology and pharmaceutical industries, Neal's expertise and customer- and patient-centric approach to sales, marketing, and commercial leadership are sure to be a tremendous asset to us as we continue to grow in the integrated infusion therapy sector.\" BioTek reMEDys provides therapy-specific patient education materials and its National Customer Support Center is available 24 hours a day, seven days a week to help patients and their loved ones manage critical aspects of care. By servicing very specific disease states, BioTek reMEDys\u2019 expert team can maintain its focus on patient care \u2013 making sure that dosages and treatments are appropriate. BioTek reMEDys is a multi-site national integrated infusion therapy provider focused on providing support to people with rare diseases. Through supply chain management, innovative technology and trained specialty pharmacists, BioTek reMEDys is able to deliver superior service at a lower cost. The company bridges the gap between managed care, physicians and patients by facilitating the authorization, procurement and administration of specialty medications and infusions. BioTek reMEDys provides high-touch therapies, biologics and pharmaceuticals to support treatment for patients with rare diseases and chronic conditions, ensuring the highest quality of care. For information visit www.biotekrx.com . Story Continues View source version on businesswire.com: https://www.businesswire.com/news/home/20250123777414/en/ Contacts Media Contact: Paul Williams paul@medialinecommunications.com 310/569-0023 View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ADMA", "date": "2025-01-23T20:03:00", "sentiment": {"score": 0.5253680450841784, "confidence": 0.5354672074317932, "probabilities": {"positive": 0.5354672074317932, "negative": 0.010099162347614765, "neutral": 0.4544335901737213}}, "embedding": [-0.16661202907562256, -0.050019100308418274, 0.046401411294937134, -0.1782814860343933, -0.039771709591150284, -0.03156109154224396, 0.045451149344444275, 0.2324826419353485, 0.06269047409296036, 0.011206144466996193, -0.17245405912399292, 0.07970330864191055, 0.05627022311091423, 0.04316127300262451, 0.007932490669190884, -0.0331706665456295, -0.009490319527685642, -0.017015941441059113, -0.03179324045777321, 0.014071477577090263, -0.06231468543410301, 0.088592030107975, 0.00180096086114645, 0.005980914458632469, -0.12476879358291626, 0.03490138426423073, 0.0068322885781526566, -0.03640657663345337, -0.18366551399230957, -0.08792825788259506, 0.07601328194141388, 0.10016003996133804, -0.03199239820241928, -0.03312709182500839, -0.0810069814324379, 0.1641818881034851, -0.20702165365219116, 0.05026090145111084, -0.0716405138373375, 0.0004250509664416313, -0.04709527641534805, -0.050040509551763535, -0.13106076419353485, 0.02493978664278984, 0.07478785514831543, -0.18310829997062683, -0.13394692540168762, 0.003972502890974283, 0.07578720897436142, -0.017533591017127037, -0.21530555188655853, -0.11307348310947418, 0.013678664341568947, 0.0539122000336647, 0.057809799909591675, 0.03061757981777191, -0.04478220269083977, -0.04323355481028557, -0.09054848551750183, -0.08463673293590546, 0.08614294230937958, -0.09634573757648468, -0.047548845410346985, 0.035060904920101166, 0.05739432945847511, -0.02525399811565876, 0.07467292249202728, 0.05298146232962608, -0.0446527898311615, -0.07409150898456573, 0.03924120217561722, -0.0675726905465126, 0.05691695213317871, 0.0921514704823494, 0.04192375764250755, 0.16522520780563354, 0.07027535140514374, 0.06405871361494064, 0.05966716259717941, -0.026605594903230667, 0.16198240220546722, 0.11023341119289398, 0.008274717256426811, 0.06466488540172577, -0.12365111708641052, 0.03950735926628113, 0.02222730591893196, 0.03496628999710083, -0.02338661067187786, -0.024641025811433792, 0.12890830636024475, 0.037149034440517426, 0.05642084777355194, -0.10587562620639801, -0.0840654969215393, -0.05948783457279205, -0.030237527564167976, -0.013550261035561562, 0.021503977477550507, 0.018694579601287842, 0.025924300774931908, -0.03455614671111107, -0.12794560194015503, -0.054655879735946655, -0.10345549881458282, -0.12371008843183517, -0.047074805945158005, 0.027390040457248688, 0.0815170481801033, 0.028950639069080353, -0.11946865916252136, 0.007499756291508675, -0.08874375373125076, -0.07166653126478195, -0.07370498031377792, 0.1937538981437683, -0.08302042633295059, 0.039430171251297, 0.1658141314983368, -0.03500346094369888, 0.01928476244211197, 0.05613991618156433, -0.04629053175449371, -0.09656689316034317, 0.06275095045566559, 0.07927770912647247, 0.027748126536607742, 6.900025473684114e-33, 0.07595010101795197, 0.06982394307851791, 0.03397582098841667, 0.04756661504507065, 0.05743071064352989, 0.10262193530797958, -0.0034713479690253735, -0.04881449416279793, -0.08608677983283997, -0.03111100196838379, -0.1962427943944931, 0.1281459927558899, -0.03734207525849342, 0.04367540031671524, -0.18314212560653687, -0.09040284156799316, -0.128951758146286, 0.03496195375919342, -0.08644646406173706, 0.09782109409570694, 0.0375695675611496, -0.06810138374567032, -0.06848053634166718, 0.2056998610496521, -0.019439730793237686, -0.013390576466917992, -0.10448823869228363, 0.09227035939693451, 0.1417723149061203, 0.012196706607937813, -0.07908796519041061, 0.04388514161109924, -0.0031460607424378395, -0.06734512001276016, -0.13570517301559448, -0.10913458466529846, -0.12752892076969147, -0.13965508341789246, 0.11104709655046463, -0.012846294790506363, -0.12464237213134766, 0.09791015088558197, -0.04417429864406586, 0.006324945017695427, 0.06638874858617783, -0.011189276352524757, -0.05346404388546944, 0.025922361761331558, 0.04245931655168533, 0.002295539714396, -0.052336614578962326, -0.026186011731624603, 0.15290170907974243, -0.09527543187141418, 0.047001369297504425, 0.004352185875177383, -0.022899916395545006, -0.001187625341117382, 0.1139880120754242, 0.10051515698432922, 0.11343898624181747, -0.009106835350394249, -0.06339523196220398, 0.008366366848349571, -0.01730520650744438, 0.008875674568116665, 0.09575723111629486, -0.04552965611219406, 0.003282565623521805, 0.06744382530450821, -0.09396062791347504, 0.024754855781793594, 0.12987802922725677, 0.08301182091236115, -0.02865132875740528, -0.07618338614702225, -0.02148047275841236, 0.03550635278224945, -0.07293638586997986, 0.037936437875032425, -0.03994137421250343, 0.003242054022848606, -0.02259969338774681, 0.10649353265762329, 0.12410256266593933, -0.039607733488082886, -0.04893408343195915, -0.003996905870735645, -0.09199969470500946, 0.023472711443901062, -0.004152356181293726, 0.036292899399995804, -0.06264656782150269, 0.19170954823493958, 0.00475677102804184, -9.725506143457952e-33, 0.07106458395719528, -0.07431413233280182, -0.04224284738302231, 0.008707767352461815, 0.06457673013210297, 0.11713771522045135, 0.05671259015798569, -0.12489200383424759, 0.1296629160642624, -0.052247606217861176, 0.07076650112867355, 0.15526723861694336, -0.039756760001182556, -0.04091653972864151, -0.11065806448459625, -0.003679766785353422, -0.11444632709026337, -0.08682028204202652, -0.08782260119915009, 0.07862727344036102, -0.0216236412525177, 0.1834561824798584, -0.10788105428218842, 0.03631971776485443, -0.003525156993418932, 0.0057333679869771, 0.017094405367970467, 0.08807690441608429, 0.07065412402153015, 0.010882100090384483, 0.005116068758070469, -0.1224423199892044, -0.2489558458328247, 0.04130149260163307, 0.008272068575024605, 0.010389478877186775, 0.07667937129735947, -0.05076871067285538, 0.04726123437285423, 0.05154157429933548, 0.10689890384674072, -0.04633539542555809, -0.04701385274529457, 0.029926801100373268, 0.07048654556274414, -0.062404535710811615, -0.08294497430324554, -0.11329539120197296, 0.035320624709129333, -0.01900472119450569, -0.1104181706905365, 0.06686773896217346, 0.0051557766273617744, 0.011077169328927994, -0.0418144054710865, -0.0539308562874794, 0.040266264230012894, -0.039484068751335144, 0.02631746232509613, -0.011573504656553268, 0.045955389738082886, -0.05916852504014969, 0.039440080523490906, 0.03041280247271061, -0.034292303025722504, 0.16650056838989258, 0.15601809322834015, 0.02220798283815384, 0.06245028227567673, -0.07646991312503815, -0.05804663151502609, -0.033478617668151855, 0.03039110265672207, -0.16766485571861267, 0.0431375689804554, 0.03349051997065544, -0.16571757197380066, -0.1138872504234314, -0.1461252123117447, -0.009861679747700691, 0.027094587683677673, -0.07913795113563538, -0.03928742557764053, 0.047372400760650635, -0.0032952511683106422, 0.023007553070783615, 0.17339861392974854, 0.002721976488828659, -0.03930840641260147, 0.02756153792142868, -0.10970781743526459, -0.04290984570980072, -0.03828997164964676, 0.06067444011569023, -0.028314203023910522, -1.0148617235472557e-07, 0.07710124552249908, -0.04171361029148102, 0.06453029066324234, -0.008494320325553417, 0.09443627297878265, -0.08536234498023987, -0.05476550757884979, 0.021609947085380554, 0.04428941756486893, 0.1993142068386078, -0.0029486031271517277, 0.1187744289636612, -0.11986778676509857, 0.02595715969800949, 0.17520764470100403, 0.014561563730239868, -0.11729545891284943, 0.16181455552577972, -0.09713849425315857, -0.03540685027837753, -0.034637562930583954, 0.08885376155376434, 0.008394377306103706, -0.07988753914833069, 0.1582634299993515, 0.004136293660849333, 0.09429289400577545, -0.01604500785470009, 0.030872326344251633, -0.06075379252433777, -0.032244227826595306, -0.02843562141060829, 0.06410843878984451, 0.0775115042924881, -0.04351247847080231, -0.11052007973194122, 0.04292217269539833, 0.0454099215567112, 0.04157920926809311, 0.023084361106157303, -0.10302605479955673, -0.019354648888111115, -0.06784113496541977, 0.03291330486536026, -0.052815746515989304, -0.050412487238645554, -0.07120714336633682, 0.04681231081485748, -0.010218274779617786, -0.05663975328207016, -0.003085409291088581, 0.06888230890035629, 0.00698664877563715, -0.02932172641158104, -0.019806358963251114, 0.05886467918753624, 0.02742498554289341, -0.09550458192825317, -0.03400726243853569, -0.023432567715644836, -0.11149279773235321, -0.09575805068016052, 0.16503357887268066, -0.04678922891616821], "changes": {"1wk": -2.895051534650646}}, {"text": "ADMA Biologics Inc. (ADMA): Why Should You Buy This Growth Stock For The Next 5 Years? Maham Fatima Sat, Jan 18, 2025, 10:01 PM 5 min read In This Article: ADMA +1.98% We recently compiled a list of the 15 Best Growth Stocks to Buy for the Next 5 Years . In this article, we are going to take a look at where ADMA Biologics Inc. (NASDAQ:ADMA) stands against the other growth stocks. Kevin Mahn, President & CIO at Hennion & Walsh Asset Management, recently appeared on CNBC on January 6 to discuss the current market momentum and emphasize the need for investors to be selective in 2025 to find growth opportunities. He highlighted that while the MAG7 have led the market recently, their leadership may not continue. Mahn referenced historical data, noting that since 1950, there have been nine instances where the market rallied by 20% or more, with the market rising in eight of those cases. However, he pointed out that gains in the following year averaged only 3.6%, indicating a need for careful selection. He also acknowledged recent market trends, including a decline in the S&P 500's performance and a potential shift in investor sentiment following events like the Santa Claus Rally. He predicted a path of lower interest rates, expecting 50 basis points of cuts this year instead of the previously anticipated 100 basis points. Mahn suggested that this environment would create favorable conditions for stocks and bonds but urged investors to diversify beyond mega-cap tech stocks into sectors like biotech and aerospace. Earlier on January 3 as well, Mahn noted that after two consecutive years of gains, a third year of strong performance appears unlikely. He remarked that it seems the Grinch got in the way of the Santa Claus rally this year. He also addressed concerns from investors tempted to time the market or sell their holdings. He warned against trying to time the market, describing it as often futile. Instead, he advocated for rebalancing portfolios to align with long-term goals and risk tolerance. He suggested that the economic landscape is changing, with lower interest rates and stagnant economic growth expected moving forward. Mahn advised investors to take profits from sectors that previously led the market and consider reallocating those funds into different areas poised for future growth. He highlighted biotech as a promising sector, noting bipartisan agreement on the need to lower drug prices. This shift could lead large-cap pharmaceutical companies to seek new revenue sources, making smaller biotech firms attractive. Methodology We first sifted through online rankings, and internet lists to compile a list of the top growth stocks to buy for the next 5 years. We then selected the stocks with high 5-year revenue growth and high analysts' upside potential. From those we picked 15 stocks that were the most popular among elite hedge funds and that analysts were bullish on. The stocks are ranked in ascending order of the number of hedge funds that have stakes in them, as of Q3 2024. Story Continues Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter\u2019s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points ( s ee more details here ). An independent distributor in their pharmacy with a range of biopharmaceutical products on display. ADMA Biologics Inc. (NASDAQ: ADMA ) Number of Hedge Fund Holders: 25 5-Year Revenue CAGR: 78.09% Upside Potential as of January 15: 50.06% ADMA Biologics Inc. (NASDAQ:ADMA) is a biopharmaceutical company that develops and commercializes specialty plasma-derived biologics. These are medicines created from human plasma that target specific medical conditions. Using its expertise in immunology, the company has brought three products to the market, providing innovative treatments for patients with infectious diseases and compromised immune systems. The company achieved a revenue of $119.8 million in Q3 2024, a 78% year-over-year increase, driven by its commercialization efforts. This translated to a net income of $35.9 million, a substantial 1,300% surge compared to the year-ago period. These results led the company to raise its full-year guidance for revenue and net income. Mizuho Securities analyst Anthony Petrone recently maintained a Buy rating on ADMA Biologics Inc. (NASDAQ:ADMA), citing these earnings. This growth is driven by ASCENIV, which is a treatment for primary immunodeficiency (PI) patients. The company has adjusted its production schedule to boost ASCENIV output for accelerated earnings growth. To support this trajectory, it has implemented several initiatives, including donor retention programs to enhance high-titer plasma collections and partnerships with third-party plasma collectors. ADMA Biologics Inc. (NASDAQ:ADMA) forecasts significant revenue opportunities for ASCENIV, projecting it to become a billion-dollar product by the 2030s. Overall ADMA ranks 14th on our list of the best growth stocks to buy for the next 5 years. As we acknowledge the growth potential of ADMA as an investment, our conviction lies in the belief that AI stocks hold great promise for delivering high returns and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than ADMA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock . READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap . Disclosure: None. This article is originally published at Insider Monkey . View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ADMA", "date": "2025-01-18T22:01:56", "sentiment": {"score": 0.3691520690917969, "confidence": 0.5794991254806519, "probabilities": {"positive": 0.5794991254806519, "negative": 0.21034705638885498, "neutral": 0.21015381813049316}}, "embedding": [-0.03336350619792938, -0.04705267399549484, 0.0006722602993249893, 0.017210429534316063, 0.08376835286617279, 0.01763271912932396, -0.02072002738714218, 0.0955311506986618, 0.00016203336417675018, 0.06546803563833237, -0.09691999852657318, 0.1218579113483429, -0.07017921656370163, -0.03612590208649635, -0.0064588915556669235, 0.07997109740972519, -0.1586594581604004, -0.03350429981946945, -0.013999614864587784, 0.14319318532943726, -0.0827082097530365, -0.023581206798553467, -0.020375559106469154, -0.017451714724302292, 0.023116815835237503, 0.07158935815095901, -0.00312881451100111, 0.018868280574679375, -0.17603573203086853, 0.005573470611125231, 0.011640964075922966, 0.15024955570697784, 0.10531744360923767, -0.009024498984217644, -0.08695753663778305, 0.033450137823820114, -0.05572236329317093, 0.1011086106300354, 0.09875227510929108, 0.00872807763516903, 0.04259353503584862, -0.08909900486469269, -0.07112213969230652, -0.07886645197868347, 0.05633849650621414, -0.1736670881509781, 0.05945950746536255, -0.042763881385326385, 0.09521285444498062, -0.0477396659553051, -0.2969481647014618, -0.05894916132092476, -0.05661602318286896, -0.06241326406598091, -0.1083124428987503, 0.05833887308835983, -0.09009968489408493, -0.02820223942399025, 0.006832156330347061, -0.026063086465001106, 0.05082271993160248, -0.03957056999206543, 0.059148382395505905, -0.019732343032956123, 0.15029276907444, -0.06622684746980667, 0.03353741392493248, 0.036522336304187775, -0.015217049047350883, 0.12076907604932785, 0.1490372121334076, 0.00914391316473484, -0.05869650840759277, -0.08936084806919098, -0.0840921550989151, 0.039321888238191605, 0.06588409841060638, 0.10248520970344543, 0.23314820230007172, -0.06869981437921524, 0.0711822509765625, -0.017632994800806046, -0.11298584938049316, -0.11639103293418884, -0.12380661070346832, -0.012300747446715832, 0.015709543600678444, -0.039719484746456146, 0.07180190831422806, -0.025350280106067657, 0.08670906722545624, -0.027812745422124863, -0.12972360849380493, 0.14189964532852173, 0.05350077897310257, -0.002036595717072487, -0.10910598933696747, 0.008332127705216408, 0.0034014061093330383, 0.06189148128032684, 0.10398270189762115, 0.16475123167037964, -0.0502205491065979, -0.04231811314821243, -0.0590665340423584, -0.22523173689842224, 0.006084431894123554, 0.005006833001971245, 0.03484282270073891, 0.029694464057683945, -0.08154849708080292, 0.11058124899864197, -0.09264406561851501, -0.07677121460437775, -0.08903886377811432, 0.08977168798446655, -0.11898359656333923, -0.057869382202625275, 0.02257968671619892, 0.10515817999839783, 0.05355602130293846, 0.07581591606140137, -0.03709470108151436, 0.03707710653543472, 0.061694443225860596, -0.0009353188797831535, -0.16365648806095123, 9.263384049319186e-33, 0.018702128902077675, -0.01187235675752163, 0.01943890005350113, 0.06942947208881378, -0.1203140914440155, 0.03189190849661827, -0.0032428998965770006, -0.14373627305030823, -0.07701265066862106, -0.11420281231403351, -0.06989619135856628, 0.15429019927978516, -0.11594894528388977, 0.09232081472873688, 0.10249029099941254, -0.1369517743587494, -0.07596008479595184, -0.0031697750091552734, 0.08429042994976044, -0.08314606547355652, 0.01199528481811285, 0.03658158332109451, -0.14954356849193573, 0.05318129062652588, 0.03234119713306427, 0.07465362548828125, -0.027614988386631012, 0.03827349841594696, -0.006534125655889511, 0.08692432940006256, -0.004955942276865244, 0.04173997417092323, -0.1405741423368454, -0.13699845969676971, 0.003926179371774197, -0.042640913277864456, -0.11721419543027878, -0.041722413152456284, 0.04372211545705795, -0.017760448157787323, -0.04705388844013214, 0.075152188539505, -0.02016238123178482, -0.025008659809827805, 0.02061057835817337, 0.07478772103786469, -0.04478609561920166, 0.01527130976319313, -0.0606563575565815, 0.04218306019902229, 0.024016806855797768, 0.002403619699180126, 0.014574458822607994, -0.049348630011081696, -0.012426404282450676, -0.044151678681373596, -0.1298140585422516, -0.07504902780056, -0.060591116547584534, 0.10054232180118561, -0.0009072404354810715, -0.010242275893688202, -0.03420498967170715, 0.10190866887569427, -0.24998006224632263, 0.21931186318397522, 0.07181183993816376, 0.11342449486255646, -0.08328505605459213, 0.247584268450737, 0.10285535454750061, -0.0575287863612175, 0.01280469261109829, -0.06501635909080505, 0.015643702819943428, -0.053069107234478, 0.00040755048394203186, 0.11027390509843826, -0.0677604153752327, 0.0572451651096344, 0.060111891478300095, -0.06469555199146271, 0.013902528211474419, -0.012554533779621124, -0.03744111582636833, -0.008056437596678734, 0.07882128655910492, 0.016053810715675354, 0.05999874696135521, -0.05547534301877022, -0.008704027161002159, 0.03998156636953354, -0.007768516894429922, 0.13675937056541443, -0.038154542446136475, -1.2546583117520022e-32, -0.08360180258750916, -0.0756547749042511, -0.03238508850336075, 0.004768380895256996, -0.09156832098960876, -0.0034442837350070477, 0.06590782850980759, 0.008404158055782318, 0.007422406226396561, -0.10532758384943008, -0.06141450256109238, 0.04943770915269852, 0.04545247182250023, 0.08120820671319962, -0.126095250248909, -0.010855811648070812, 0.03328593075275421, -0.08336922526359558, 0.07652156054973602, -0.013052504509687424, 0.06173042207956314, 0.23189277946949005, -0.16919897496700287, 0.13518835604190826, 0.015694910660386086, 0.027406416833400726, -0.06898133456707001, 0.05547016113996506, -0.01297234371304512, -0.07751137763261795, -0.06584778428077698, -0.048603884875774384, -0.06083819270133972, 0.08330734074115753, 0.016796883195638657, 0.059328749775886536, 0.01224365085363388, -0.12264998257160187, -0.07198242843151093, 0.1176951676607132, 0.0894864872097969, 0.04059779271483421, 0.037313662469387054, -0.0342460572719574, 0.07644371688365936, 0.046553026884794235, 0.11529594659805298, 0.08854395151138306, 0.16139154136180878, 0.10856464505195618, 0.016747446730732918, 0.05248531699180603, 0.055462419986724854, -0.02316834218800068, -0.1224718764424324, 0.03690262883901596, -0.05609717220067978, 0.011300880461931229, -0.06425276398658752, 0.010965801775455475, -0.03441046178340912, 0.08026926964521408, -0.02444113977253437, -0.11240591108798981, -0.06730834394693375, 0.027357343584299088, 0.04478120431303978, -0.13119465112686157, -0.0521651953458786, -0.13099561631679535, 0.07230456173419952, -0.0889076441526413, -0.00721176341176033, -0.023708203807473183, -0.09767428040504456, 0.1382317990064621, -0.04875314235687256, 0.02238580211997032, -0.05681874230504036, -0.019483378157019615, -0.07530046254396439, 0.09971623867750168, 0.05686144158244133, 0.022533778101205826, -0.10974757373332977, 0.17597511410713196, -0.06063859164714813, -0.1842883825302124, -0.16252285242080688, -0.01698138937354088, -0.05000017583370209, -0.14945882558822632, -0.04878011345863342, 0.014843851327896118, -0.0988493338227272, -1.007309293754588e-07, 0.07918897271156311, -0.0004915501922369003, 0.01809675619006157, -0.031448185443878174, 0.16949951648712158, -0.016694795340299606, -0.0010875111911445856, 0.02297193557024002, 0.1948927491903305, 0.19661745429039001, 0.13517603278160095, 0.1266835331916809, -0.1304008662700653, 0.10972754657268524, -0.10057316720485687, -0.0026527708396315575, -0.1132177785038948, -0.07521046698093414, -0.04779589921236038, -0.10126395523548126, 0.055534616112709045, 0.07143373042345047, 0.07076127827167511, 0.02955021522939205, 0.041489556431770325, -0.03138451650738716, 0.006137003190815449, -0.006173534318804741, -0.04989802837371826, 0.008284090086817741, -0.036040231585502625, -0.059071414172649384, 0.024811116978526115, 0.0463600754737854, -0.026905518025159836, 0.007205002475529909, 0.053554270416498184, -0.012966331094503403, 0.034107986837625504, 0.04368944466114044, 0.0012102723121643066, -0.054222479462623596, 0.11086200922727585, -0.03755425661802292, -0.026008479297161102, -0.10038034617900848, -0.07460170239210129, 0.006261602975428104, 0.15380796790122986, -0.1239737719297409, -0.01048803236335516, 0.003898643422871828, -0.017104411497712135, 0.024760883301496506, 0.03549883887171745, 0.045248933136463165, -0.13921669125556946, 0.018033988773822784, -0.10992944240570068, -0.02883795276284218, 0.08448143303394318, -0.22225137054920197, -0.07813051342964172, 0.12455981969833374], "changes": {"1wk": -0.4950490375089082}}, {"text": "The Brutalist director Brady Corbet faces backlash for AI, issues statement Dan Girolamo Tue, Jan 21, 2025, 1:30 AM 2 min read A24 One of the contenders at the 2025 Oscars now faces a major controversy. The Brutalist , one of the most championed movies of 2024, is facing backlash for its use of AI. Over the weekend, Red Shark News published an interview with editor D\u00e1vid Jancs\u00f3, who revealed The Brutalist used AI tools from the Ukrainian special Respeecher to make small tweaks to the Hungarian dialogue spoken by Adrien Brody and Felicity Jones. Jancs\u00f3 also mentioned how AI was used to make the architectural designs and buildings in The Brutalist\u2019s closing sequence. The AI news has sparked outrage within the film community, with some suggesting The Brutalist should be disqualified from awards contention. Director Brady Corbet released a statement to clarify the AI use, stating the actors\u2019 portrayals are \u201ccompletely their own\u201d and that the AI \u201cpreserved the authenticity\u201d of said performances. \u201cAdrien and Felicity\u2019s performances are completely their own,\u201d Corbet said in a statement via Deadline . \u201cThey worked for months with dialect coach Tanera Marshall to perfect their accents. Innovative Respeecher technology was used in Hungarian language dialogue editing only, specifically to refine certain vowels and letters for accuracy. No English language was changed. This was a manual process, done by our sound team and Respeecher in post-production. The aim was to preserve the authenticity of Adrien and Felicity\u2019s performances in another language, not to replace or alter them and done with the utmost respect for the craft.\u201d The Brutalist | Official Trailer 2 HD | A24 In the issue over the film\u2019s final sequence involving architectural blueprints, Corbet said, \u201cJudy Becker and her team did not use AI to create or render any of the buildings. All images were hand-drawn by artists. To clarify, in the memorial video featured in the background of a shot, our editorial team created pictures intentionally designed to look like poor digital renderings circa 1980.\u201d Corbet finished with this statement: \u201c\u2018The Brutalist\u2019 is a film about human complexity, and every aspect of its creation was driven by human effort, creativity, and collaboration. We are incredibly proud of our team and what they\u2019ve accomplished here.\u201d The Brutalist is now in theaters . View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ADMA", "date": "2025-01-21T01:30:01", "sentiment": {"score": -0.2509373612701893, "confidence": 0.2931956350803375, "probabilities": {"positive": 0.04225827381014824, "negative": 0.2931956350803375, "neutral": 0.6645461320877075}}, "embedding": [-0.12495085597038269, 0.0292514581233263, -0.049877189099788666, -0.05841537192463875, 0.03934355825185776, 0.052225369960069656, -0.03185206279158592, 0.054041776806116104, 0.09184039384126663, -0.012704433873295784, -0.104630246758461, -0.041465841233730316, 0.0694664791226387, 0.04946058616042137, -0.12652716040611267, -0.045685775578022, 0.11291376501321793, 0.0519876703619957, -0.13437634706497192, -0.005618674214929342, 0.06275978684425354, 0.07705160230398178, -0.010054936632514, -0.08779831975698471, -0.05679601430892944, -0.047572266310453415, -0.013292231597006321, 0.004764767829328775, -0.14655253291130066, 0.042185235768556595, -0.010817491449415684, -0.03661822900176048, -0.0071526383981108665, 0.00176035868935287, -0.08960092067718506, 0.11110257357358932, 0.06368785351514816, -0.06840179860591888, -0.05160186067223549, -0.019171690568327904, -0.09656552970409393, 0.001679382985457778, -0.07141415774822235, 0.04461812227964401, 0.16576437652111053, -0.031450431793928146, -0.12334130704402924, -0.06953541189432144, -0.05510293319821358, -0.017915457487106323, -0.21430397033691406, -0.043079227209091187, -0.043930135667324066, -0.07956274598836899, -0.11819083243608475, -0.016185777261853218, 0.051595862954854965, 0.04829756170511246, 0.06727755814790726, -0.09615068137645721, 0.07317160069942474, -0.01886977069079876, 0.06113070994615555, 0.08912249654531479, 0.06624947488307953, -0.05990171059966087, 0.10311141610145569, -0.013110511004924774, -0.0025913803838193417, 0.07947774231433868, 0.030374087393283844, -0.0849391296505928, 0.12282212823629379, -0.041500285267829895, -0.034062255173921585, -0.0156085304915905, -0.046661652624607086, -0.02982114627957344, 0.0021887330804020166, -0.21023288369178772, 0.2191794365644455, -0.15236437320709229, 0.028456445783376694, -0.003054383210837841, -0.06370199471712112, 0.09613644331693649, 0.02138921432197094, -0.08363580703735352, 0.05115147680044174, 0.10901346802711487, 0.033419933170080185, -0.0720747709274292, 0.0799064040184021, 0.037029929459095, 0.1345505714416504, -0.09626244008541107, -0.03505934029817581, 0.11824942380189896, -0.07474963366985321, 0.0935627818107605, -0.07830125838518143, -0.04896751791238785, -0.13685624301433563, -0.08899033814668655, 0.04286497086286545, -0.11832207441329956, 0.00987126026302576, -0.04452752321958542, -0.16647668182849884, -0.013970636762678623, -0.11389113962650299, -0.004857092164456844, 0.006561434827744961, -0.1301741898059845, 0.2197248786687851, 0.018267087638378143, -0.027719000354409218, 0.020950116217136383, 0.05789388343691826, 0.13668480515480042, 0.1319294273853302, 0.02010231837630272, -0.11701178550720215, 0.07004840672016144, 0.08122880756855011, -0.019597558304667473, -0.012949853204190731, 8.245311901959019e-33, 0.12218319624662399, 0.05036264657974243, 0.05310888588428497, -0.0030491796787828207, -0.012174002826213837, -0.10871999710798264, -0.08151516318321228, 0.07006566226482391, 0.008577615022659302, -0.04396294429898262, 0.02681075967848301, -0.07471108436584473, -0.11872538179159164, 0.13538727164268494, 0.03553245961666107, 0.038327656686306, -0.04292414337396622, 0.0048538558185100555, -0.06551086902618408, 0.007309573236852884, -0.06992118060588837, 0.19740073382854462, -0.03140221908688545, -0.020790377631783485, -0.1306067258119583, 0.08013559132814407, 0.09876473248004913, -0.07531660050153732, -0.03905642777681351, 0.027581525966525078, -0.2656795084476471, 0.0040626199916005135, -0.0075842635706067085, 0.045516788959503174, 0.0351870134472847, -0.05436117574572563, -0.13092485070228577, -0.11110017448663712, 0.0010384800843894482, 0.0837375819683075, 0.048200275748968124, 0.024421386420726776, -0.161839097738266, -0.08257010579109192, -0.010792486369609833, 0.13811014592647552, -0.002556541468948126, 0.07895584404468536, 0.02643534541130066, 0.06511174142360687, 0.10629792511463165, 0.17107129096984863, 0.099357470870018, 0.11257196962833405, 0.055068276822566986, 0.035378262400627136, 0.04287850111722946, -0.0835772380232811, 0.12776638567447662, -0.03834008052945137, -0.031590934842824936, 0.10490307956933975, -0.016870969906449318, 0.17457209527492523, -0.03357464820146561, 0.12877212464809418, 0.013248978182673454, 0.08243625611066818, 0.13037201762199402, -0.07024510949850082, -0.23293671011924744, -0.09667347371578217, 0.0949842631816864, 0.03219643980264664, -0.11187329143285751, -0.022835196927189827, 0.07077562063932419, -0.01819242723286152, -0.034223522990942, -0.041379984468221664, -0.05347105488181114, 0.11456432938575745, 0.03307686001062393, -0.08030631393194199, -0.0997840091586113, -0.06098899990320206, -0.0027635893784463406, -0.022845515981316566, 0.07746614515781403, 0.060862064361572266, 0.03048376739025116, -0.1036582887172699, -0.08052981644868851, 0.04087011143565178, -0.061667416244745255, -9.302394298719162e-33, -0.04111017659306526, -0.07308445870876312, -0.29397645592689514, 0.08667033165693283, -0.035887185484170914, -0.015485959127545357, -0.12355557084083557, -0.03134223446249962, 0.14767567813396454, -0.03975830227136612, 0.007564222440123558, -0.12133213132619858, -0.006550732534378767, -0.02665558271110058, 0.07540081441402435, -0.08323155343532562, -0.027096059173345566, -0.07102400064468384, 0.017266418784856796, 0.0006770844338461757, 0.22451958060264587, 0.08371856063604355, -0.10299713909626007, -0.07790010422468185, 0.03169626370072365, 0.021157732233405113, -0.02350621297955513, 0.12278122454881668, 0.06296110153198242, -0.09153120964765549, 0.0893937200307846, -0.10271776467561722, -0.12979008257389069, 0.06329254060983658, 0.017150504514575005, 0.12936288118362427, 0.08147668838500977, -0.013930055312812328, -0.12957443296909332, 0.06394600123167038, 0.05574021115899086, -0.04634816572070122, -0.1674017608165741, 0.10314968973398209, 0.028471875935792923, -0.075236976146698, -0.05824822187423706, -0.154067263007164, 0.01358086708933115, -0.11316464841365814, 0.027886196970939636, 0.008190280757844448, -0.09088223427534103, -0.09373247623443604, -0.057040050625801086, -0.058120157569646835, 0.07288474589586258, -0.10913161188364029, 0.10614494979381561, 0.13240839540958405, 0.0009704760159365833, -0.0005389824509620667, -0.07253488898277283, -0.11477110534906387, 0.11278566718101501, 0.010771205648779869, -0.0026061581447720528, -0.031534161418676376, -0.13888677954673767, 0.019313842058181763, 0.0384531132876873, 0.004365650936961174, 0.0026857454795390368, 0.041931286454200745, 0.013272909447550774, -0.004316014237701893, -0.052871592342853546, 0.021282581612467766, -0.12330155074596405, 0.022057048976421356, -0.07993075251579285, -0.13267084956169128, 0.1755853146314621, 0.16737927496433258, 0.015773650258779526, 0.16572660207748413, -0.07899317890405655, 0.03229218348860741, -0.0292776208370924, 0.1479419320821762, 0.10470706969499588, -0.010161549784243107, 0.1167675256729126, 0.06887257844209671, -0.0724925696849823, -1.003108778263595e-07, -0.037652526050806046, 0.09457024186849594, 0.02277570404112339, 0.025527028366923332, -0.007193672936409712, -0.10195670276880264, 0.018586698919534683, 0.03539770841598511, -0.03560252487659454, 0.02981356903910637, 0.06985288113355637, -0.009687752462923527, -0.013981446623802185, 0.058111079037189484, -0.05730466917157173, 0.12441026419401169, -0.06752646714448929, 0.043425802141427994, -0.06533515453338623, 0.021098870784044266, 0.09346411377191544, 0.017752600833773613, -0.01975402794778347, -0.15846793353557587, -0.018402379006147385, 0.005150944925844669, -0.05610936880111694, 0.02596461772918701, -0.09164723008871078, 0.1799958050251007, -0.04646043851971626, -0.003724253736436367, 0.04681198671460152, -0.0911513939499855, -0.04481411725282669, 0.02694203332066536, 0.0877031534910202, -0.02767319791018963, -0.03658962994813919, 0.02070753462612629, 0.009680410847067833, 0.0636235773563385, 2.562320514698513e-05, 0.03676852583885193, 0.2137579768896103, -0.012992145493626595, -0.010343572124838829, -0.17068390548229218, -0.030256297439336777, -0.03211110085248947, 0.0026119763497263193, -0.00083491753321141, -0.12079239636659622, 0.12969404458999634, 0.2150273323059082, -0.020650330930948257, -0.0012863946612924337, -0.013959875330328941, -0.036004699766635895, 0.11700950562953949, 0.0631106048822403, 0.0903257504105568, 0.17342858016490936, 0.03627820312976837], "changes": {"1wk": 0.1856478151533657}}, {"text": "Adma Biologics (ADMA) Stock Sinks As Market Gains: Here's Why Zacks Equity Research Wed, Jan 15, 2025, 1:50 AM 2 min read In This Article: ADMA +1.98% In the latest trading session, Adma Biologics (ADMA) closed at $16.32, marking a -1.03% move from the previous day. The stock's change was less than the S&P 500's daily gain of 0.12%. On the other hand, the Dow registered a gain of 0.52%, and the technology-centric Nasdaq decreased by 0.23%. The the stock of infectious disease drug developer has fallen by 13.12% in the past month, lagging the Medical sector's loss of 2.25% and the S&P 500's loss of 3.45%. The investment community will be closely monitoring the performance of Adma Biologics in its forthcoming earnings report. In that report, analysts expect Adma Biologics to post earnings of $0.15 per share. This would mark year-over-year growth of 275%. Meanwhile, our latest consensus estimate is calling for revenue of $112.2 million, up 51.83% from the prior-year quarter. Investors should also take note of any recent adjustments to analyst estimates for Adma Biologics. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability. Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model. Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 13.55% decrease. Adma Biologics is currently a Zacks Rank #3 (Hold). Digging into valuation, Adma Biologics currently has a Forward P/E ratio of 24.61. This indicates a premium in contrast to its industry's Forward P/E of 22.48. The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 58, putting it in the top 24% of all 250+ industries. The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Story Continues ADMA Biologics Inc (ADMA) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ADMA", "date": "2025-01-15T01:50:20", "sentiment": {"score": -0.721500463783741, "confidence": 0.8376172780990601, "probabilities": {"positive": 0.11611681431531906, "negative": 0.8376172780990601, "neutral": 0.04626593738794327}}, "embedding": [-0.0695871114730835, -0.03674798086285591, -0.04344155639410019, 0.006365735083818436, -0.04036602005362511, -0.08079107850790024, 0.0022675329819321632, 0.1683824360370636, 0.1187233030796051, 0.14974050223827362, -0.15720367431640625, 0.15470534563064575, -0.06099478900432587, 0.0015092664398252964, -0.0922137051820755, 0.0461762435734272, -0.038770854473114014, -0.02799881249666214, -0.0910528153181076, 0.13468709588050842, -0.040777746587991714, 0.04741305857896805, 0.044031426310539246, -0.0036131227388978004, 0.05961746722459793, 0.00379285030066967, -0.037719398736953735, 0.016825105994939804, -0.2012069821357727, -0.08955417573451996, -0.05221967399120331, 0.07976239174604416, 0.14479200541973114, -0.0978965163230896, -0.03984852880239487, -0.0680399090051651, -0.08461163938045502, 0.05358929559588432, 0.14275391399860382, 0.08579762279987335, -0.008822187781333923, 0.025313353165984154, -0.16326746344566345, -0.023093007504940033, -0.07607115805149078, -0.19589382410049438, -0.031051676720380783, 0.05908314511179924, 0.09742993116378784, 0.08160299062728882, -0.2503910958766937, -0.08188985288143158, -0.02498360350728035, 0.02231452241539955, -0.0793541967868805, 0.0551939457654953, -0.09832636266946793, -0.16684435307979584, 0.001076993066817522, 0.032925523817539215, 0.046376511454582214, 0.08254791796207428, 0.02897508069872856, 0.03934357315301895, 0.23221449553966522, -0.05311155691742897, 0.025145377963781357, 0.06167633458971977, -0.07125350087881088, 0.018498944118618965, 0.04628307372331619, -0.00503136869519949, -0.0723218321800232, 0.01588193140923977, -0.14576667547225952, 0.11561699211597443, 0.07552184164524078, 0.07329471409320831, 0.1736064851284027, -0.1557239294052124, 0.09684902429580688, -0.04801652207970619, -0.12659357488155365, -0.043505411595106125, -0.04605014622211456, -0.009419523179531097, 0.1454809159040451, 0.1374436467885971, 0.14277510344982147, 0.0228985957801342, 0.07578840851783752, -0.08203421533107758, -0.01519625075161457, 0.004871886223554611, 0.026539374142885208, 0.008778675459325314, -0.06018921732902527, -0.08399499952793121, 0.045069754123687744, 0.06231135502457619, 0.014843612909317017, 0.0981641337275505, -0.035254161804914474, -0.13633808493614197, 0.007754714693874121, -0.12944626808166504, 0.012762203812599182, -0.029757795855402946, 0.05698808655142784, 0.1112699955701828, -0.03175874054431915, 0.11926604807376862, -0.11191858351230621, -0.036923713982105255, -0.09249790012836456, 0.14635586738586426, -0.05357044190168381, -0.02647201158106327, 0.13331833481788635, 0.04545825347304344, 0.10903239250183105, 0.06995256245136261, 0.01150854304432869, -0.04608159139752388, 0.09776023030281067, 0.05310189723968506, -0.1523195505142212, 6.604833128253714e-33, 0.03917623311281204, 0.08625613152980804, 0.05218452960252762, -0.02738933451473713, -0.055956728756427765, 0.000326705165207386, 0.03354280814528465, -0.1194416880607605, -0.060233768075704575, -0.039171405136585236, -0.22868287563323975, 0.1609845757484436, -0.057862475514411926, 0.06739304214715958, -0.02579832635819912, -0.06382682919502258, 0.014791099354624748, 0.032538387924432755, -0.02107129991054535, -0.039024852216243744, -0.04801999032497406, 0.018768124282360077, -0.14932285249233246, 0.05460845306515694, 0.03242615610361099, 0.01295611821115017, -0.12458780407905579, 0.07551415264606476, -0.07939577847719193, 0.07099073380231857, 0.022082827985286713, 0.02258365973830223, -0.01480783335864544, -0.12984147667884827, 0.02409953996539116, -0.07922431081533432, -0.04024466127157211, 0.012418067082762718, 0.15739887952804565, 0.027720341458916664, -0.10221053659915924, 0.022161800414323807, -0.10258550941944122, -0.09434881806373596, 0.0032702884636819363, 0.05645797401666641, -0.13001954555511475, 0.027603480964899063, -0.06085023283958435, -0.033036310225725174, -0.04988621920347214, -0.01918806880712509, 0.05878821015357971, -0.05808660387992859, -0.13160967826843262, -0.023870356380939484, -0.04066595435142517, -0.19446209073066711, 0.00808674655854702, 0.16193440556526184, 0.021406201645731926, 0.2094109058380127, 0.05260535329580307, 0.0001746099442243576, -0.25171753764152527, 0.13365402817726135, 0.05979805812239647, 0.0405195876955986, -0.08138764649629593, 0.17963913083076477, 0.02533138543367386, 0.012323901057243347, 0.14166881144046783, -0.09035484492778778, 0.04588715732097626, -0.03876372054219246, -0.013000930659472942, -0.015167481265962124, -0.011555906385183334, 0.10979916155338287, -0.04151655361056328, -0.06243198364973068, -0.06107275187969208, 0.0627768412232399, 0.04988228529691696, 0.0008044847054407, 0.0024688048288226128, 0.05779753625392914, -0.016021814197301865, -0.02975216880440712, 0.023511389270424843, 0.028861897066235542, -0.13535791635513306, 0.14583943784236908, 0.01809120923280716, -9.306781096699637e-33, -0.1430940181016922, 0.03879813477396965, -0.006552712060511112, 0.011824414134025574, -0.11196616291999817, 0.01168125681579113, 0.09978377819061279, 0.17242297530174255, -0.001968737691640854, -0.022492151707410812, -0.037626899778842926, 0.07198655605316162, -0.14267325401306152, 0.035064972937107086, 0.009428394958376884, -0.010028396733105183, -0.008941760286688805, -0.0995054617524147, -0.0016109501011669636, 0.024201519787311554, 0.006325053051114082, 0.25006377696990967, -0.12058163434267044, 0.18905523419380188, 0.09716203808784485, 0.03518088161945343, -0.010258981958031654, 0.14141857624053955, 0.016054850071668625, -0.12218624353408813, -0.022876586765050888, -0.012362129986286163, -0.11841455101966858, 0.05595427006483078, -0.033783141523599625, 0.007064012810587883, 0.05333929508924484, -0.21974816918373108, 0.001651240512728691, -0.0541868582367897, 0.12791694700717926, 0.012670764699578285, 0.02032400295138359, 0.03264300152659416, 0.16480641067028046, 0.044614750891923904, 0.09282737970352173, 0.0002650246024131775, 0.18136554956436157, 0.04692969471216202, 0.03867335245013237, 0.011071497574448586, 0.020594734698534012, 0.08551935106515884, -0.10870790481567383, 0.014397558756172657, -0.0949021726846695, -0.02014557272195816, -0.12355883419513702, 0.03367520123720169, 0.0371173620223999, 0.08261290192604065, 0.01891585811972618, 0.005106602795422077, -0.08565731346607208, 0.040907129645347595, 0.13922816514968872, -0.07660331577062607, 0.020902354270219803, -0.11470414698123932, 0.06434403359889984, -0.024526793509721756, 0.05349674075841904, -0.11770075559616089, -0.022903433069586754, 0.19671772420406342, -0.09558583796024323, -0.1137336939573288, -0.08414027839899063, 0.006790193263441324, 0.028880519792437553, 0.0414787232875824, 0.06111336499452591, 0.025264227762818336, -0.11266286671161652, 0.10416150093078613, 0.011958649381995201, -0.0497703030705452, -0.14718745648860931, 0.014994759112596512, -0.08882183581590652, -0.15650948882102966, -0.12375181913375854, -0.005228936206549406, -0.017150530591607094, -1.004486165356866e-07, 0.09704022109508514, -0.009135628119111061, 0.10408803820610046, -0.07982039451599121, 0.14323316514492035, -0.013899259269237518, 0.0438428595662117, 0.05402800440788269, 0.17461171746253967, 0.1611180156469345, 0.06971213966608047, 0.09309474378824234, -0.26672548055648804, 0.11520250141620636, -0.1279139667749405, 0.054273854941129684, -0.11913317441940308, 0.013904519379138947, -0.06615874916315079, -0.1802763044834137, -0.027305638417601585, 0.11522964388132095, 0.10747279971837997, -0.05957711860537529, 0.05150063335895538, -0.08438043296337128, -0.02130120061337948, -0.03645150735974312, -0.019011951982975006, -0.029072236269712448, 0.04272779822349548, -0.012338749133050442, 0.001082385191693902, 0.13833776116371155, -0.04002342373132706, -0.14756813645362854, 0.0980062335729599, -0.02337314561009407, 0.04260050505399704, 0.1159881204366684, -0.027662668377161026, -0.08170785009860992, -0.004934293683618307, -0.0328725203871727, -0.048832233995199203, -0.06575439870357513, -0.12888972461223602, 0.04579348489642143, 0.13047920167446136, -0.2786426544189453, 0.11783893406391144, -0.05179203301668167, -0.04798010736703873, -0.049536678940057755, -0.037614721804857254, 0.04883655160665512, -0.15124627947807312, -0.015313918702304363, -0.18413960933685303, -0.02945941872894764, 0.09966699033975601, -0.23634806275367737, -0.012742038816213608, 0.1044851541519165], "changes": {"1wk": -0.9803912402207475}}, {"text": "ADMA Stock Catapults 275.7% in a Year: How Should You Play the Stock? Zacks Equity Research Fri, Jan 10, 2025, 9:41 PM 4 min read In This Article: ADMA +1.98% ADMA Biologics ADMA shares have skyrocketed 275.7% in a year against the industry\u2019s decline of 14.3%. The stock has also outperformed the sector and the S&P 500 during the aforementioned period. ADMA also hit a 52-week high of $23.64 on Nov. 11. The stupendous rally can be attributed to the company\u2019s consistently strong quarterly performance and raised guidance. ADMA Outperforms Industry, Sector & S&P 500 Zacks Investment Research Image Source: Zacks Investment Research Asceniv\u2019s Performance Fuels ADMA\u2019s Growth ADMA Biologics markets plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases. The company\u2019s top line currently comprises sales of three FDA-approved products \u2014 Bivigam (an Intravenous Immune Globulin [\u201cIVIG\u201d] product to treat primary humoral immunodeficiency), Asceniv (to treat primary immunodeficiency disease or PIDD) and Nabi-HB (to treat and provide enhanced immunity against the hepatitis B virus). Asceniv, its lead product, is a plasma-derived IVIG that contains naturally occurring polyclonal antibodies. These antibodies are proteins used by the body\u2019s immune system to neutralize microbes, such as bacteria and viruses, and prevent infection and disease. Asceniv is indicated for the treatment of PIDD or inborn errors of immunity in adults and adolescents. It is manufactured using ADMA\u2019s unique, patented plasma donor screening methodology and tailored plasma pooling design, which blends normal source plasma with respiratory syncytial virus plasma obtained from donors tested using the company\u2019s proprietary microneutralization assay. Total revenues in the third quarter jumped 78% due to increased sales of Asceniv and third-party plasma sales by ADMA\u2019s BioCenters business segment. ADMA\u2019s Efforts to Expand Asceniv\u2019s Label In connection with the FDA\u2019s approval of Asceniv in April 2019, ADMA is required to conduct a pediatric study to evaluate the safety and efficacy of Asceniv in children and adolescents. The ongoing post-marketing study for Asceniv may provide a label expansion opportunity to include pediatric-aged PI patients. All pediatric patients in Asceniv\u2019s post-marketing pediatric study have now completed their treatment schedule.\u00a0 ADMA expects to file its supplemental biologics license application over the coming quarters, with a potential approval for label expansion in the first half of 2026. A potential label expansion should strengthen ADMA\u2019s product portfolio. ADMA\u2019s Financial Targets While reporting third-quarter results, ADMA raised its outlook for 2024 and 2025 once again. ADMA now expects to generate revenues of more than $415 million in 2024 and $465 million in 2025 (previous guidance: more than $400 million in 2024 and $445 million in 2025). Net income is projected to exceed $120 million in 2024 and $165 million in 2025 (up from the prior guidance of $105 million for 2024 and $155 million for 2025). Story Continues Margin Improvement ADMA\u2019s higher-margin product portfolio now accounts for more than 50% of its total revenues. The company is working to increase Asceniv's supply. If successful, Asceniv will account for a significant portion of ADMA's total revenues over time, further advancing its potential margin expansion and earnings growth. Valuation & Estimates Going by the price/sales ratio, ADMA\u2019s shares currently trade at 8.86x forward sales, higher than its mean of 3.31x and the industry\u2019s 1.69x. Zacks Investment Research Image Source: Zacks Investment Research Estimate Movement The estimate for 2024 and 2025 earnings per share has remained stable at 52 cents and 78 cents, respectively over the past 60 days. Zacks Investment Research Image Source: Zacks Investment Research Conclusion ADMA Biologics, which competes with Takeda TAK and Grifols GRFS in the U.S. market for plasma-derived products, should maintain momentum in the upcoming quarters. Incremental additional penetration of Asceniv should accelerate near-term revenue growth. The targeted market has significant growth potential. Management expects additional opportunities for ADMA to continue to grow substantially in the underserved, immune-compromised and co-morbid patient population despite the availability of standard-of-care therapy. However, the exceptional rally witnessed by the stock might limit any further gains. We advise investors to wait for now. For investors already owning the stock, staying invested would be a prudent move. ADMA currently carries a Zacks Rank #3 (Hold).\u00a0 You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here . Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Grifols, S.A. (GRFS) : Free Stock Analysis Report ADMA Biologics Inc (ADMA) : Free Stock Analysis Report Takeda Pharmaceutical Co. (TAK) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ADMA", "date": "2025-01-10T21:41:00", "sentiment": {"score": 0.8628525724634528, "confidence": 0.8711320757865906, "probabilities": {"positive": 0.8711320757865906, "negative": 0.00827950332313776, "neutral": 0.12058841437101364}}, "embedding": [-0.04964069277048111, -0.011157245375216007, -0.08553704619407654, -0.08130481839179993, -0.0468982495367527, 0.000947415828704834, -0.011207642033696175, 0.2550002634525299, -0.018617378547787666, 0.04688463360071182, -0.12967927753925323, 0.07822335511445999, 0.0540592297911644, 0.008665325120091438, -0.03278283774852753, 0.05418664216995239, 0.05613330379128456, 0.07880797237157822, -0.021246619522571564, 0.012314418330788612, 0.009716027416288853, 0.0051888469606637955, 0.002822752110660076, -0.033906757831573486, -0.05695603787899017, 0.08731687068939209, -0.13290223479270935, -0.07385004311800003, -0.18115466833114624, -0.1071963906288147, -0.05571600794792175, 0.08375976234674454, 0.16203489899635315, -0.118370920419693, -0.024001238867640495, -0.010951467789709568, -0.16532935202121735, 0.06198451668024063, -0.09662923216819763, 0.027520490810275078, -0.016728179529309273, -0.01369490846991539, -0.1273401528596878, -0.0973195731639862, 0.01465731579810381, -0.17622125148773193, -0.10958820581436157, 0.0925728976726532, 0.10093118995428085, 0.18120762705802917, -0.2122931033372879, -0.038018599152565, -0.022504277527332306, 0.07630978524684906, -0.0870351642370224, 0.01770920865237713, -0.17175625264644623, -0.11725097894668579, -0.06852271407842636, -0.024916406720876694, -0.0012964904308319092, 0.005599540192633867, 0.006098155863583088, -0.01486808992922306, 0.17075462639331818, 0.005131836980581284, 0.07344470918178558, -0.0009831002680584788, -0.019523538649082184, -0.016101034358143806, 0.11575989425182343, 0.020866651087999344, -0.1242126077413559, 0.17648789286613464, -0.10989074409008026, 0.2465335577726364, 0.09540143609046936, 0.07118520885705948, 0.17704656720161438, -0.08713008463382721, 0.10580458492040634, 0.08002675324678421, -0.007385222241282463, 0.07431736588478088, 0.022778358310461044, 0.017313620075583458, -0.06029517948627472, 0.10553355515003204, 0.04048096388578415, 0.040953002870082855, 0.13349345326423645, 0.02905946597456932, -0.033543601632118225, 0.02196536213159561, 0.04868435114622116, -0.06174460053443909, -0.03859373927116394, 0.0022424887865781784, 0.08728578686714172, -0.010628647170960903, -0.04529496654868126, 0.0009535355493426323, -0.06087876111268997, -0.09412848949432373, -0.04371325299143791, -0.1250801682472229, 0.02449565939605236, -0.07570351660251617, 0.16233700513839722, 0.12136201560497284, -0.0202409029006958, 0.01848546974360943, -0.05074991658329964, -0.17354068160057068, -0.08654648065567017, 0.23628054559230804, -0.07189608365297318, -0.00859952811151743, 0.20506376028060913, 0.0027059298008680344, 0.08328127861022949, 0.0766201764345169, 0.07975472509860992, 0.008976721204817295, 0.16772529482841492, -0.03942719101905823, -0.08714227378368378, 9.57548147288235e-33, -0.08132371306419373, 0.04625648632645607, 0.10367748141288757, 0.10596555471420288, -0.11994679272174835, 0.007316787261515856, 0.09577077627182007, -0.10730159282684326, -0.06983368843793869, -0.10360872745513916, -0.1720156967639923, 0.1420903205871582, 0.020800326019525528, 0.22403883934020996, -0.01923738792538643, -0.08723144978284836, 0.03442323952913284, -0.066993348300457, -0.013968357816338539, 0.023397188633680344, -0.015695208683609962, -0.008594125509262085, -0.052687644958496094, 0.1436433345079422, -0.053074002265930176, -0.028560824692249298, -0.05210237205028534, 0.10042814910411835, -0.040099915117025375, 0.07392313331365585, -0.009076347574591637, -0.0010828692466020584, -0.0068739065900444984, -0.15682268142700195, -0.0653986930847168, -0.09442970901727676, -0.19045321643352509, -0.07898745685815811, -0.009122789837419987, 0.07818955183029175, -0.02790093421936035, -0.00760912150144577, -0.08507214486598969, -0.016850411891937256, 0.09988625347614288, 0.04530009999871254, -0.17353126406669617, 0.007204819470643997, 0.0010683517903089523, -0.02224295400083065, 0.019998328760266304, 0.05888725072145462, -0.0006173746660351753, -0.12000752985477448, -0.06664050370454788, -0.03339743614196777, -0.09423315525054932, -0.09903571754693985, 0.014492145739495754, 0.1906346082687378, -0.044796183705329895, 0.07256174087524414, -0.04812803864479065, 0.11024726182222366, -0.25277483463287354, 0.0873412936925888, 0.109632208943367, -0.04491577297449112, -0.128567636013031, 0.07592403888702393, 0.03907066583633423, -0.030857447534799576, 0.13498108088970184, -0.0009356681257486343, 0.02258819341659546, -0.060367897152900696, 0.0625915601849556, 0.16119056940078735, -0.01647968962788582, -0.014329846948385239, -0.10944628715515137, -0.027233289554715157, -0.0035878121852874756, 0.11658976227045059, -0.04150070622563362, -0.037175629287958145, 0.02113063633441925, 0.06246209144592285, -0.06025087088346481, -0.05505162477493286, 0.0970323234796524, 0.05104566738009453, -0.14938494563102722, 0.1606084108352661, -0.007268975488841534, -1.1089072243572113e-32, -0.11959138512611389, -0.012934042140841484, 0.009189103730022907, -0.0291373822838068, -0.1308457851409912, 0.15585674345493317, 0.2158002257347107, -0.015772517770528793, 0.08806081861257553, -0.013314507901668549, -0.011338046751916409, 0.09204717725515366, -0.045829854905605316, 0.003159642219543457, -0.05231091380119324, 0.03524402529001236, -0.005030346103012562, 0.00810711458325386, -0.08754591643810272, 0.03875822573900223, 0.05811607837677002, 0.26585760712623596, -0.005649274215102196, 0.11575697362422943, 0.05902610346674919, -0.03377537056803703, -0.04695283621549606, 0.0703761950135231, 0.07793214917182922, -0.03181764483451843, 0.03440859913825989, 0.03422730788588524, -0.15806902945041656, 0.08183503895998001, -0.006257183849811554, -0.031864650547504425, 0.059354688972234726, -0.17441625893115997, -0.03803786635398865, -0.13863131403923035, -0.04424593597650528, 0.020713087171316147, -0.01666044257581234, -0.0378434881567955, 0.1386161744594574, 0.08394463360309601, 0.11514323949813843, -0.04635965824127197, 0.12243066728115082, 0.054361894726753235, 0.006488620303571224, 0.028243843466043472, 0.09402695298194885, 0.011734802275896072, -0.10339996963739395, -0.02544086053967476, -0.008055942133069038, -0.03549234941601753, -0.062082163989543915, 0.03877394646406174, 0.09308337420225143, 0.04175756871700287, 0.05358629301190376, -0.022866714745759964, -0.030222661793231964, 0.14534683525562286, 0.16969019174575806, -0.054387930780649185, -0.003203036729246378, -0.14413240551948547, -0.050272729247808456, 0.0013813246041536331, 0.07612919807434082, -0.04897197335958481, -0.03517533093690872, 0.08916661143302917, -0.030552897602319717, 0.0074777016416192055, -0.09718891233205795, -0.061254777014255524, -0.0478263683617115, -0.1226295754313469, 0.001949273981153965, 0.06898005306720734, -0.004668712615966797, 0.015562564134597778, 0.023360319435596466, -0.09103761613368988, -0.0669889748096466, 0.17780494689941406, -0.13593830168247223, -0.07569148391485214, -0.14498311281204224, 0.058659836649894714, 0.07889838516712189, -1.0088332658142463e-07, 0.1607237011194229, -0.028586501255631447, 0.033156294375658035, -0.08433577418327332, 0.09342941641807556, -0.02689100056886673, -0.060388267040252686, 0.042511072009801865, 0.09688044339418411, 0.12514062225818634, -0.018494442105293274, 0.1119205579161644, -0.18536348640918732, -0.02036890760064125, -0.03603876009583473, -0.01798565313220024, -0.09162044525146484, 0.0025530774146318436, -0.05437484383583069, -0.04505906254053116, -0.0025604460388422012, 0.061322059482336044, -0.012471720576286316, -0.10744062066078186, -0.004338707774877548, -0.09627190232276917, 0.09110386669635773, -0.05318022519350052, 0.08468946069478989, -0.17575189471244812, -0.007781682536005974, -0.06102670356631279, 0.05648600310087204, 0.009255336597561836, -0.08261430263519287, -0.06255864351987839, 0.16047224402427673, -0.024744752794504166, 0.1064886525273323, 0.15144135057926178, -0.0777650773525238, -0.08593978732824326, 0.08431892842054367, -0.07436888664960861, -0.05241664871573448, -0.028694070875644684, -0.22332528233528137, -0.02371249347925186, 0.06755875051021576, -0.07828045636415482, -0.044378265738487244, -0.013723098672926426, -0.07714278995990753, -0.06924188137054443, -0.10755559802055359, 0.12035471200942993, -0.11257214844226837, -0.13442543148994446, 0.005441531538963318, -0.010524195618927479, 0.06534148752689362, -0.17123524844646454, 0.10834240168333054, 0.09840408712625504], "changes": {"1wk": -13.685339877512451}}, {"text": "ADMA Biologics Announces Preliminary Full Year 2024 Revenue and Provides Business Update ADMA Biologics, Inc. Mon, Jan 13, 2025, 3:00 PM 6 min read In This Article: ADMA +1.98% ADMA Biologics, Inc. FY 2024 Preliminary Unaudited Total Revenue of Approximately $417-425 Million, Exceeding Previous Guidance of $415 Million YE 2024 Total Cash Grew to More than $100 Million, an Increase of Approximately $45 Million Q-o-Q, Notwithstanding $30 Million of Debt Organically Discharged During 4Q 2024 Newly Executed High Titer Plasma Supply Contracts Expected to Provide Foundation for Durable ASCENIV Revenue Growth Through Late 2030s PAS Submitted to the FDA for Approval of Innovative Yield Enhancement Production Process; Potential Regulatory Approval Anticipated Mid-2025 FY 2025 and 2026 Total Revenue Guidance Expected to Exceed $485 Million and $600 Million, Respectively FY 2025 and 2026 Net Income Expected to Exceed $170 Million and $230 Million, Respectively FY 2025 and 2026 Adjusted EBITDA (1) Expected to Exceed $220 Million and $300 Million, Respectively ADMA Anticipates Generating Greater Than $1 Billion in Total Annual Revenue Prior to 2030, More Than Doubling the Current 2025 Revenue Forecast RAMSEY, N.J. and BOCA RATON, Fla., Jan. 13, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (\u201cADMA\u201d or the \u201cCompany\u201d), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced its preliminary unaudited full year 2024 revenue and provided a business update. Based on unaudited financial information, ADMA preliminarily estimates that its total revenue for the full year ended December 31, 2024 will be between $417-425 million. ADMA\u2019s total cash holdings at year-end 2024 grew to greater than $100 million, representing a net cash surplus relative to the $75 million of total debt currently outstanding with Ares Capital. \u201cWe are proud of our 2024 performance and the meaningful impact our products have had on improving the lives of immunodeficient patients. Building on this momentum, we believe we are well-positioned to deliver continued stockholder value in 2025,\u201d said Adam Grossman, President and Chief Executive Officer of ADMA. \u201cCompelling real-world patient outcomes for ASCENIV have driven record forward-looking demand metrics through year-end 2024, underpinning both revenue and margin growth into the new year. We are pleased to announce that we have now executed multiple, long-term third-party plasma supply contracts, contributing to a continuous and growing supply of high-titer plasma expected to meet ASCENIV\u2019s growth targets through the late 2030s. These supply agreements should position us to potentially achieve $1 billion in total annual revenue before 2030, with significant growth potential in the 2030s. We deeply appreciate the commitment of our plasma supply partners to ADMA and the immunodeficient patients we serve.\u201d Story Continues Mr. Grossman continued, \u201cOur innovative yield enhancement production process is advancing, with a Prior Approval Supplement (PAS) recently filed with the FDA. Pending an anticipated mid-year approval, this enhancement is expected to increase Immunoglobulin (IG) yields by approximately 20% from the same starting plasma volume, driving substantial revenue and earnings increases beginning later this year and accelerating during 2026.\u201d Mr. Grossman concluded, \u201cWe\u2019ve built a commercial biopharma organization capable of executing our strategy and delivering robust growth. Prior to 2030, we anticipate doubling forecasted 2025 total revenue with even greater earnings expansion during the same period. We remain dedicated to advancing what we believe will be a leading growth story in the healthcare sector for years to come, while continuing to make a meaningful difference in the lives of immunodeficient patients.\u201d Financial Guidance: FY 2025 and 2026 total revenue expected to exceed $485 million and $600 million, respectively FY 2025 and 2026 net income expected to exceed $170 million and $230 million, respectively FY 2025 and 2026 Adjusted EBITDA expected to exceed $220 million and $300 million, respectively Greater than $1 billion of total annual revenue expected to be achieved prior to 2030, with anticipated outsized earnings growth from current margin levels Recent Business Updates & 2025 Objectives: Favorably evolving product mix. With record highs across all ASCENIV leading demand metrics through year-end 2024, the Company expects ASCENIV\u2019s total revenue share to expand in 2025 and beyond. As ASCENIV\u2019s benefit in real-world patient outcomes continues and long-term high-titer plasma supply contracts ramp up, the Company anticipates accelerating ASCENIV\u2019s penetration and significantly expanding its peak revenue potential beyond current levels. Regulatory filings submitted for potential approval of innovative yield enhancement production process. ADMA successfully submitted a PAS for potential approval of its innovative yield enhancement production process. Following FDA review of the submission, the Company anticipates a mid-2025 approval, with potential revenue and earnings accretion expected in the second half of the year. This innovative process has demonstrated an ability to increase production yields by approximately 20% from the same starting plasma volume, potentially driving significant increases to financial targets, if approved. Solidified high titer plasma supply on a long-term basis. ADMA has recently executed third-party, high titer plasma supply contracts, which are expected to significantly increase access to raw material plasma used to produce ASCENIV. These long-term agreements should allow the Company to source high titer plasma from approximately 250 collection centers, a 5-fold increase in total collection capacity. Combined with ADMA\u2019s growing internal plasma collections, the Company should be well-positioned to meet its revenue targets and potentially achieve $1 billion in total annual revenue prior to 2030, with continued potential growth opportunities thereafter. Strengthened balance sheet and optimizing cost of capital. ADMA generated approximately $45 million in operating cash flow in the fourth quarter of 2024, increasing year-end cash on hand to over $100 million. With this robust cash flow and $60 million in debt organically discharged over the past two quarters, ADMA now holds a net cash surplus relative to the $75 million of total outstanding debt with Ares Capital. The Company anticipates further balance sheet improvements in 2025, driven by projected Adjusted EBITDA growth, sustained cash generation, and continued optimization of its capital structure. Leveraging robust IP estate and innovative R&D engine. ADMA anticipates generating initial animal data for its lead R&D pipeline program, SG-001, targeting S. pneumonia . If approved, SG-001 represents upside to the currently provided financial guidance, and ADMA believes the product has the potential to generate $300-500 million in high margin annual revenue. (1) Adjusted EBITDA is a non-GAAP financial measure. The estimated Adjusted EBITDA amounts included herein are preliminary and reconciliations cannot be produced at this time without unreasonable effort. The Company expects to provide a reconciliation of Adjusted EBITDA to the most comparable GAAP measure in its earnings release relating to the fourth quarter and full year 2024 financial results. About ADMA Biologics, Inc. (ADMA) ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM \u00ae (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV\u2122 (immune globulin intravenous, human \u2013 slra 10% liquid) for the treatment of PI; and NABI-HB \u00ae (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., which provides its blood plasma for the manufacture of its products. ADMA\u2019s mission is to manufacture, market and develop specialty plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA holds numerous U.S. and foreign patents related to and encompassing various aspects of its products and product candidates. For more information, please visit www.admabiologics.com . Cautionary Note Regarding Forward-Looking Statements This press release contains \u201cforward-looking statements\u201d pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about ADMA Biologics, Inc. (\u201cwe,\u201d \u201cour\u201d or the \u201cCompany\u201d). Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain such words as \u201cconfident,\u201d \u201cestimate,\u201d \u201cproject,\u201d \u201cintend,\u201d \u201cforecast,\u201d \u201ctarget,\u201d \u201canticipate,\u201d \u201cplan,\u201d \u201cplanning,\u201d \u201cexpect,\u201d \u201cbelieve,\u201d \u201cwill,\u201d \u201cis likely,\u201d \u201cwill likely,\u201d \u201cshould,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cmay,\u201d \u201cpotential\u201d or, in each case, their negative, or words or expressions of similar meaning. These forward-looking statements include, but are not limited to, statements about the Company\u2019s full-year 2024 total revenue; revenue, net income, Adjusted EBITDA and margins guidance in future periods and related timing in connection therewith; our balance sheet; the benefits of newly executed high titer plasma supply agreements and impact on ASCENIV growth and financial performance; the status of the yield enhancement production process submission and the anticipated impact of potential FDA approval on production yields and financial targets and related timing; ASCENIV revenue share and growth; ability to deliver stockholder value; ability to make timely filings with the U.S. Securities and Exchange Commission (SEC); and statements regarding SG-001 and revenue potential. Actual events or results may differ materially from those described in this press release due to a number of important factors. Current and prospective security holders are cautioned that there also can be no assurance that the forward-looking statements included in this press release will prove to be accurate. Except to the extent required by applicable laws or rules, ADMA does not undertake any obligation to update any forward-looking statements or to announce revisions to any of the forward-looking statements. Forward-looking statements are subject to many risks, uncertainties and other factors that could cause our actual results, and the timing of certain events, to differ materially from any future results expressed or implied by the forward-looking statements, including, but not limited to, the risks and uncertainties described in our filings with the SEC, including our most recent reports on Form 10-K, 10-Q and 8-K, and any amendments thereto. INVESTOR RELATIONS CONTACT: Argot Partners | 212-600-1902 | ADMA@argotpartners.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ADMA", "date": "2025-01-13T15:00:00", "sentiment": {"score": 0.9226883621886373, "confidence": 0.9355577230453491, "probabilities": {"positive": 0.9355577230453491, "negative": 0.012869360856711864, "neutral": 0.051572978496551514}}, "embedding": [-0.08166814595460892, -0.01864204742014408, -0.0243859700858593, -0.12011028081178665, -0.10771935433149338, -0.1376122087240219, -0.016955189406871796, 0.13834397494792938, 0.05058744549751282, 0.11170898377895355, -0.12719231843948364, -0.022440850734710693, -0.10379421710968018, -0.014107409864664078, -0.06639827787876129, 0.07671167701482773, -0.0011640284210443497, -0.02065599337220192, -0.04143454134464264, 0.09221742302179337, 0.10580763965845108, 0.09093739092350006, -0.039450615644454956, -0.02747448720037937, 0.0055982377380132675, -0.013439127244055271, -0.057492054998874664, -0.08276626467704773, -0.18869361281394958, -0.0334860160946846, 0.04708690941333771, 0.09849864989519119, 0.12252235412597656, -0.1228329986333847, 0.04698358103632927, 0.036101385951042175, -0.09341685473918915, 0.07820455729961395, 0.03476617485284805, 0.06230955570936203, -0.020266445353627205, -0.04142962768673897, -0.14874167740345, -0.004705199971795082, 0.02444099448621273, -0.1709514856338501, -0.042446818202733994, -0.004775058478116989, 0.08427293598651886, 0.18936672806739807, -0.1438470482826233, -0.0613047257065773, 0.028223736211657524, 0.06962675601243973, -0.01593005284667015, -0.013808750547468662, -0.06490866839885712, -0.1408674120903015, -0.11537551879882812, 0.048616815358400345, -0.04090622439980507, -0.03210684284567833, 0.013155216351151466, -0.03306805342435837, 0.14495182037353516, -0.027099236845970154, 0.046776361763477325, -0.059272438287734985, -0.11270181089639664, -0.00699816457927227, 0.09500375390052795, -0.008352508768439293, -0.018800415098667145, 0.007907819002866745, -0.06209437549114227, 0.13830365240573883, 0.12538239359855652, 0.1739083230495453, 0.16006231307983398, -0.17085371911525726, 0.13499213755130768, 0.021657602861523628, -0.045142821967601776, -0.0962742269039154, -0.10845628380775452, 0.018345952033996582, 0.0783337652683258, 0.12422827631235123, 0.13312697410583496, 0.08201978355646133, 0.04396244138479233, -0.11334516853094101, -0.01075100526213646, -0.007906649261713028, -0.0872223824262619, -0.010973306372761726, -0.042276810854673386, -0.1117013618350029, 0.1565982848405838, -0.02106361836194992, -0.01226251944899559, 0.05447954311966896, -0.03249773010611534, -0.1587546318769455, -0.021152399480342865, -0.11496474593877792, -0.0014878418296575546, 0.020567968487739563, 0.05524371191859245, 0.12968891859054565, -0.02088208869099617, 0.0052919755689799786, -0.01789274625480175, -0.019730808213353157, -0.04530118778347969, 0.2147064059972763, -0.16621555387973785, -0.011075901798903942, 0.18757778406143188, -0.07078009843826294, 0.06451916694641113, 0.09002714604139328, 0.005353700835257769, 0.04137363284826279, 0.07748019695281982, -0.0084101976826787, -0.13526782393455505, 1.5068672368766473e-32, 0.03255292773246765, -0.004724283702671528, 0.10906586050987244, 0.02829044498503208, -0.05558731406927109, 0.08009620755910873, 0.04293467476963997, -0.027215031906962395, -0.07499290257692337, -0.07832004874944687, -0.14511412382125854, 0.12339668720960617, -0.03984037786722183, 0.2097976803779602, -0.0464213527739048, -0.1212773397564888, -0.016673024743795395, -0.005994182080030441, 0.04036705940961838, 0.030060183256864548, -0.019153207540512085, -0.0029820390045642853, -0.11901341378688812, 0.13580508530139923, 0.0018529640510678291, 0.12330381572246552, -0.12403751164674759, 0.061915088444948196, 0.024977777153253555, 0.08138720691204071, -0.073416568338871, 0.008104061707854271, 0.08901199698448181, -0.12457752227783203, -0.009663458913564682, -0.08781932294368744, -0.09294942766427994, -0.018644265830516815, 0.054369352757930756, 0.03815029188990593, 0.049325037747621536, 0.027881544083356857, -0.04405790567398071, -0.08824876695871353, -0.017870180308818817, 0.008467111736536026, -0.041202180087566376, 0.04553188011050224, -0.030658423900604248, 0.013562023639678955, -0.057397644966840744, 0.013907670974731445, 0.02302180416882038, -0.0832163617014885, -0.038834184408187866, -0.10055014491081238, -0.0868927463889122, -0.10962361842393875, 0.010149993002414703, 0.1553386151790619, -0.07340114563703537, 0.12468495965003967, -0.031294673681259155, 0.13407683372497559, -0.20220601558685303, 0.15022358298301697, 0.07782351970672607, 0.017690273001790047, -0.004159687086939812, 0.14763425290584564, 0.003929615952074528, -0.053841233253479004, 0.14909158647060394, -0.03545504808425903, 0.05393791198730469, -0.042703621089458466, 0.11103621125221252, 0.038226231932640076, -0.06530776619911194, 0.14472100138664246, -0.0636601373553276, 0.027792751789093018, -0.06067414581775665, 0.08990289270877838, 0.12389965355396271, 0.02320733293890953, 0.0008862046524882317, 0.11150442063808441, -0.010259110480546951, -0.015834128484129906, 0.03528273105621338, -0.004060383886098862, -0.17508353292942047, 0.19355791807174683, -0.023589592427015305, -1.7162928696087645e-32, 0.002366601023823023, 0.0822695791721344, -0.00027580594178289175, -0.05605702847242355, -0.08585464954376221, 0.027222244068980217, 0.12790922820568085, 0.13271325826644897, 0.037192266434431076, -0.04054209962487221, -0.006610010284930468, 0.08072078227996826, -0.06574804335832596, 0.06167959049344063, -0.0785646066069603, -0.08585800230503082, -0.03306179121136665, -0.10433264076709747, -0.06375687569379807, 0.04777391627430916, 0.03713948279619217, 0.2660042643547058, -0.05015116557478905, 0.0870504379272461, 0.09862715005874634, 0.005851959343999624, 0.030005227774381638, 0.14500047266483307, -0.019370293244719505, -0.061634015291929245, -0.07552779465913773, -0.08931383490562439, -0.159831702709198, -0.014606340788304806, 0.008499952964484692, -0.08834825456142426, 0.09653566777706146, -0.10374955832958221, -0.004835812840610743, -0.058888014405965805, 0.047405093908309937, -0.012437169440090656, -0.10435274243354797, -0.008054771460592747, 0.10151804983615875, -0.014815544709563255, 0.05561760440468788, -0.032205041497945786, 0.14342817664146423, 0.03338993713259697, 0.03432153910398483, -0.002870182739570737, -0.01731126569211483, -0.0012401463463902473, -0.11922277510166168, -0.017784414812922478, -0.00458025187253952, -0.015101086348295212, 0.024833252653479576, -0.012929936870932579, 0.045426301658153534, 0.037793178111314774, 0.12376351654529572, -0.012378890998661518, -0.010272733867168427, 0.07292907685041428, 0.15431787073612213, -0.033846769481897354, -0.016549773514270782, -0.10859401524066925, 0.055327266454696655, -0.018115831539034843, -0.026963142678141594, -0.03797000274062157, 0.01947157457470894, 0.16594672203063965, -0.05970899388194084, -0.17407748103141785, -0.04002925753593445, -0.02000161074101925, -0.01603606715798378, -0.04197608679533005, 0.07051175087690353, 0.06969557702541351, -0.015321923419833183, 0.0554722361266613, -0.05369887501001358, -0.05430953949689865, -0.10705405473709106, 0.10998593270778656, -0.11549397557973862, -0.052323922514915466, -0.1145709827542305, 0.10768488049507141, 0.019136009737849236, -1.012169761338555e-07, 0.10875348746776581, 0.07913034409284592, 0.01904304325580597, -0.08595891296863556, 0.13745136559009552, -0.12413497269153595, 0.008141540922224522, 0.05665367841720581, 0.15883690118789673, 0.06759454309940338, 0.02643275260925293, 0.19496124982833862, -0.1248517632484436, 0.0721428170800209, -0.07220513373613358, 0.06145508587360382, -0.16201043128967285, -0.03248235583305359, -0.07081970572471619, -0.13567428290843964, -0.08989880979061127, 0.008747178129851818, 0.009381827898323536, -0.06954070180654526, -0.035550735890865326, -0.1989370733499527, 0.040418341755867004, 0.04461677372455597, 0.00034085637889802456, -0.10941512882709503, 0.0025530136190354824, -0.029458362609148026, -0.0007742363959550858, 0.05301626771688461, -0.048637695610523224, -0.2253480851650238, 0.006775977090001106, -0.027915220707654953, 0.020687958225607872, 0.11478878557682037, -0.014106687158346176, -0.15326257050037384, 0.030757872387766838, -0.009772432036697865, -0.02943871170282364, -0.10391467809677124, -0.16163575649261475, -0.01514282077550888, 0.07948324084281921, -0.16283664107322693, 0.024369435384869576, 0.06606830656528473, -0.0251021645963192, -0.10581066459417343, -0.01967095211148262, 0.009950114414095879, -0.1631172001361847, -0.03126535192131996, -0.12326499819755554, 0.01306866854429245, 0.10106585919857025, -0.22968178987503052, 0.0737282931804657, 0.00025910139083862305], "changes": {"1wk": -2.850208125397822}}, {"text": "Adma Biologics (ADMA) Surpasses Market Returns: Some Facts Worth Knowing Zacks Equity Research Thu, Jan 9, 2025, 1:50 AM 2 min read In This Article: ADMA +1.98% Adma Biologics (ADMA) closed the most recent trading day at $18.56, moving +1.48% from the previous trading session. This change outpaced the S&P 500's 0.16% gain on the day. Elsewhere, the Dow gained 0.25%, while the tech-heavy Nasdaq lost 0.06%. Shares of the infectious disease drug developer witnessed a loss of 4.79% over the previous month, beating the performance of the Medical sector with its loss of 5.77% and underperforming the S&P 500's loss of 2.8%. Market participants will be closely following the financial results of Adma Biologics in its upcoming release. The company is expected to report EPS of $0.17, up 325% from the prior-year quarter. Alongside, our most recent consensus estimate is anticipating revenue of $116.7 million, indicating a 57.92% upward movement from the same quarter last year. Investors should also note any recent changes to analyst estimates for Adma Biologics. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook. Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system. The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Adma Biologics is holding a Zacks Rank of #3 (Hold) right now. Digging into valuation, Adma Biologics currently has a Forward P/E ratio of 23.6. This signifies a premium in comparison to the average Forward P/E of 22.38 for its industry. The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 69, placing it within the top 28% of over 250 industries. The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Story Continues ADMA Biologics Inc (ADMA) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ADMA", "date": "2025-01-09T01:50:20", "sentiment": {"score": 0.8750291429460049, "confidence": 0.9148181676864624, "probabilities": {"positive": 0.9148181676864624, "negative": 0.039789024740457535, "neutral": 0.04539291188120842}}, "embedding": [-0.11488914489746094, -0.035240184515714645, -0.006455565802752972, 0.034552641212940216, -0.011182055808603764, -0.07139229774475098, -0.04563460499048233, 0.19445538520812988, 0.11192832887172699, 0.12764649093151093, -0.14589139819145203, 0.12413953244686127, -0.026271052658557892, 0.006199491675943136, -0.10335785895586014, -0.01354977861046791, -0.024796482175588608, -0.03928869217634201, -0.11464519798755646, 0.1177024394273758, -0.05625121295452118, 0.04732447862625122, 0.0792289450764656, -0.00019667018204927444, 0.043698620051145554, -0.03484010696411133, -0.040933072566986084, 0.05533033609390259, -0.2014128714799881, -0.11313062906265259, -0.0988076776266098, 0.12353214621543884, 0.10702091455459595, -0.07799393683671951, -0.04550407454371452, -0.05998469889163971, -0.059070441871881485, 0.03738539293408394, 0.12321566045284271, 0.055895522236824036, -0.003187194699421525, 0.028996488079428673, -0.1436609923839569, -0.0026040636003017426, -0.056100860238075256, -0.17240022122859955, -0.014359157532453537, 0.021942289546132088, 0.0735463798046112, 0.11331016570329666, -0.22801977396011353, -0.0319998636841774, -0.0593595989048481, 0.050041113048791885, -0.0663747638463974, 0.05055578052997589, -0.12092015892267227, -0.19240224361419678, -0.008966870605945587, 0.021008096635341644, 0.054055631160736084, 0.0623198077082634, 0.008164036087691784, 0.0006199302151799202, 0.20857301354408264, -0.05222513899207115, 0.03146207332611084, 0.019813312217593193, -0.08458416163921356, 0.04472127556800842, 0.050108954310417175, -0.02273993380367756, -0.08935262262821198, 0.033584412187337875, -0.14367561042308807, 0.11257417500019073, 0.07701020687818527, 0.08324841409921646, 0.14707010984420776, -0.13606278598308563, 0.10580072551965714, -0.06940224021673203, -0.13396131992340088, -0.034554071724414825, -0.0005155701655894518, -0.016162265092134476, 0.141792893409729, 0.10548554360866547, 0.1316310614347458, 0.012003791518509388, 0.10627774894237518, -0.10232941061258316, -0.01866784319281578, 0.039853621274232864, 0.05341166630387306, -0.0054562827572226524, -0.04893278330564499, -0.047409795224666595, 0.06077593192458153, 0.0637110024690628, 0.026875672861933708, 0.13417334854602814, -0.04664295166730881, -0.12136772274971008, 0.029483919963240623, -0.11998765915632248, 0.03569568693637848, -0.0065187192521989346, 0.05695771798491478, 0.06291044503450394, -0.009987159632146358, 0.10486644506454468, -0.12242692708969116, -0.009222714230418205, -0.08205286413431168, 0.14948594570159912, -0.033794812858104706, 0.0006953040137887001, 0.11250046640634537, 0.06691505759954453, 0.0852539986371994, 0.08458202332258224, 0.0443979911506176, -0.02983929216861725, 0.08561612665653229, 0.07454061508178711, -0.1263478696346283, 7.877434332713461e-33, 0.07154874503612518, 0.07847553491592407, 0.06280634552240372, -0.03900906443595886, -0.029083430767059326, 0.01984323561191559, 0.0016302317380905151, -0.11684524267911911, -0.062384456396102905, -0.02776588872075081, -0.23538148403167725, 0.19087137281894684, -0.06859777867794037, 0.03423697501420975, -0.0442427359521389, -0.05119036138057709, -0.014318307861685753, 0.04278215765953064, -0.05262969434261322, -0.016066741198301315, -0.0032203998416662216, 0.04642561078071594, -0.15962035953998566, 0.011989210732281208, 0.010652994737029076, 0.03607475757598877, -0.12897123396396637, 0.045955244451761246, -0.07794498652219772, 0.05573998764157295, -0.03623569756746292, 0.02099219523370266, -0.0005220323801040649, -0.11607424914836884, 0.010021581314504147, -0.03303966671228409, -0.043275147676467896, -0.017511799931526184, 0.1403738409280777, -0.014795556664466858, -0.10727740079164505, 0.05618946999311447, -0.13797716796398163, -0.11290845274925232, -0.007150067947804928, 0.008301847614347935, -0.15315711498260498, 0.008499166928231716, -0.08232593536376953, -0.02554640918970108, -0.057450808584690094, 0.004048194270581007, 0.07218212634325027, -0.04125707596540451, -0.14490514993667603, -0.034215494990348816, -0.01643451675772667, -0.17467418313026428, -0.00033690547570586205, 0.17671167850494385, 0.04114359989762306, 0.2088819444179535, 0.01919356733560562, -0.025449935346841812, -0.24685177206993103, 0.11977695673704147, 0.04377686232328415, 0.014401527121663094, -0.1005423292517662, 0.19002211093902588, 0.01952814683318138, 0.02468564175069332, 0.11342111229896545, -0.09734610468149185, 0.057235781103372574, -0.01663106307387352, 0.0221127737313509, 0.008354626595973969, 0.005498265381902456, 0.05646389722824097, -0.039039839059114456, -0.07103880494832993, -0.03970331698656082, 0.03915226832032204, 0.04455655813217163, -0.02463861182332039, 0.014995559118688107, 0.03121929243206978, -0.04855905473232269, -0.03747272491455078, 0.004163304343819618, 0.033051278442144394, -0.11734722554683685, 0.14714109897613525, 0.028230173513293266, -1.0247940648685502e-32, -0.15380406379699707, 0.05395790934562683, 0.018269561231136322, 0.007987601682543755, -0.0819273442029953, -0.007104278542101383, 0.08811701089143753, 0.19800825417041779, -0.02779502049088478, -0.07595578581094742, 0.007187762763351202, 0.054498203098773956, -0.1299651861190796, 0.02334105782210827, 0.040539734065532684, -0.021171316504478455, -0.024504423141479492, -0.0807725265622139, 0.03008505329489708, 0.021748138591647148, 0.012269082479178905, 0.26314908266067505, -0.10273948311805725, 0.1853359341621399, 0.06376314908266068, 0.060499418526887894, 0.006167453248053789, 0.13839884102344513, -0.025195855647325516, -0.21156132221221924, 0.018454350531101227, -0.01889224350452423, -0.11407043039798737, 0.12766143679618835, -0.029507357627153397, 0.008408604189753532, 0.07349354028701782, -0.21958135068416595, 0.016401955857872963, -0.0436648465692997, 0.12218350172042847, 0.02446867525577545, 0.010997172445058823, 0.025550831109285355, 0.14464108645915985, 0.0514870323240757, 0.09730042517185211, 0.01507556438446045, 0.20724153518676758, 0.01607712358236313, 0.034670211374759674, 0.0425974503159523, -0.010598244145512581, 0.10350047796964645, -0.11418323218822479, 0.000362372025847435, -0.10621032863855362, -0.04394662752747536, -0.09540927410125732, 0.0415382944047451, 0.05557776987552643, 0.09071147441864014, 0.00619136355817318, -0.01635839231312275, -0.060113243758678436, 0.037714406847953796, 0.1530216783285141, -0.09128110855817795, -0.012366006150841713, -0.06040886417031288, -0.0021514445543289185, -0.027754168957471848, 0.025272760540246964, -0.07974357157945633, -0.003224901854991913, 0.13862890005111694, -0.08326143771409988, -0.0962207019329071, -0.06902513653039932, -0.020287657156586647, 0.03411712870001793, 0.04107453674077988, 0.04255577176809311, -0.003542572259902954, -0.07809853553771973, 0.10064996778964996, 0.060846634209156036, -0.05474855750799179, -0.11256800591945648, 0.021749332547187805, -0.09600712358951569, -0.15613386034965515, -0.13484635949134827, -0.020364709198474884, -0.027053195983171463, -1.0019733309718504e-07, 0.11276859045028687, 0.02919846959412098, 0.07382909208536148, -0.04631936177611351, 0.13790707290172577, -0.014225803315639496, -0.014953519217669964, 0.08602124452590942, 0.1475037783384323, 0.15069597959518433, 0.11696091294288635, 0.07602177560329437, -0.27532172203063965, 0.07650540769100189, -0.11619105935096741, 0.03348744288086891, -0.11429715156555176, 0.019031386822462082, -0.04318397492170334, -0.19315561652183533, -0.05220303311944008, 0.1109115332365036, 0.12603265047073364, -0.06276790797710419, 0.0650065541267395, -0.05019843205809593, -0.005557231605052948, 0.007088009268045425, -0.009010016918182373, -0.021077563986182213, 0.05419587343931198, -0.03530927002429962, 0.012922550551593304, 0.10695214569568634, -0.08577657490968704, -0.12395142763853073, 0.1137634664773941, -0.03154898062348366, 0.0485069565474987, 0.11733397841453552, 0.018568068742752075, -0.09694825857877731, -0.032178349792957306, -0.008611142635345459, -0.01114565134048462, -0.06747801601886749, -0.09432841092348099, -0.00340700289234519, 0.10077783465385437, -0.26054707169532776, 0.09742926061153412, -0.0548144094645977, -0.014829553663730621, -0.0349016934633255, -0.056184280663728714, 0.07145397365093231, -0.16191808879375458, -0.0010467106476426125, -0.17500731348991394, -0.02480573207139969, 0.13512372970581055, -0.22792044281959534, -0.03894561156630516, 0.16103482246398926], "changes": {"1wk": -9.967674755942095}}]